SEER RESEARCH DATA RECORD DESCRIPTION

CASES DIAGNOSED IN 1973-2007*

Submission: November 2009

Follow-up Cutoff Date: December 31, 2007

Documentation Version: April 2010

Diagnosis Years: 1973-2007

Cervix in situ cases after 1995 are not included.

^{*} This documentation describes the data files in the incidence/yr1973_2007.seer9, yr1992_2007.sj_la_rg_ak, yr2000_2007.ca_ky_lo_nj, and yr2005.lo_2nd_half directories. Refer to individual variable definitions to determine the differences between the directory files.

TABLE OF CONTENTS

PATIENT ID NUMBER	11
REGISTRY ID	
MARITAL STATUS AT DX	12
RACE / ETHNICITY	12
SPANISH / HISPANIC ORIGIN	14
NHIA DERIVED HISPANIC ORIGIN	
SEX	
AGE AT DIAGNOSIS	
BIRTHDATE—YEAR	
BIRTHPLACE	
SEQUENCE NUMBERCENTRAL	
MONTH OF DIAGNOSIS	
YEAR OF DIAGNOSIS	
PRIMARY SITE	
LATERALITY	
HISTOLOGY (92-00) ICD-O-2	
BEHAVIOR (92-00) ICD-O-2	
HISTOLOGIC TYPE ICD-O-3	
BEHAVIOR CODE ICD-O-3	
GRADE	
DIAGNOSTIC CONFIRMATION	
TYPE OF REPORTING SOURCE	
EOD—TUMOR SIZE	
EOD—EXTENSION	
EOD—EXTENSION PROST PATH	
EOD—LYMPH NODE INVOLV	
REGIONAL NODES POSITIVE	
REGIONAL NODES EXAMINED	27
EOD—OLD 13 DIGIT	27
EOD—OLD 2 DIGIT	
EOD—OLD 4 DIGIT	28
CODING SYSTEM FOR EOD	28
TUMOR MARKER 1	29
TUMOR MARKER 2	30
TUMOR MARKER 3	31
CS TUMOR SIZE	32
CS EXTENSION	33
CS LYMPH NODES	
CS METS AT DX	
CS SITE-SPECIFIC FACTOR 1	
CS SITE-SPECIFIC FACTOR 2	
CS SITE-SPECIFIC FACTOR 3	
CS SITE-SPECIFIC FACTOR 4	
CS SITE-SPECIFIC FACTOR 5	
CS SITE-SPECIFIC FACTOR 6	
DERIVED AJCC T	
DERIVED AJCC I	
DERIVED AJCC N	
DERIVED AJCC M DERIVED AJCC STAGE GROUP	
DERIVED SS1977	
DEKI VED 5519//	4U

TABLE OF CONTENTS

DERIVED SS2000	
DERIVED AJCC—FLAG	41
DERIVED SS1977—FLAG	41
DERIVED SS2000—FLAG	42
CS VERSION 1 ST	42
CS VERSION LATEST	42
RX SUMM—SURG PRIM SITE	43
RX SUMM—SCOPE REG LN SUR	44
RX SUMM-SURG OTH REG/DIS	
RX SUMM-REG LN EXAMINED	45
RECONSTRUCTION-FIRST COURSE (1998-2002)	45
REASON FOR NO SURGERY	46
RX SUMM—RADIATION	
RX SUMM—RAD TO CNS	
RX SUMM—SURG/RAD SEQ	
RX SUMM-SURG TYPE	
RX SUMM—SURG SITE 98-02	51
RX SUMM—SCOPE REG 98-02	
RX SUMM—SURG OTH 98-02	
SEER RECORD NUMBER	
OVER-RIDE AGE/SITE/MORPH	
OVER-RIDE SEQNO/DXCONF	
OVER-RIDE SIT/LAT/SEQNO	
OVER-RIDE SURG/DXCONF	
OVER-RIDE SITE/TYPE	
OVER-RIDE HISTOLOGY	
OVER-RIDE REPORT SOURCE	
OVER-RIDE ILL-DEFINE SITE	
OVER-RIDE LEUK, LYMPHOMA	
OVER-RIDE SITE/BEHAVIOR	
OVER-RIDE SITE/EOD/DX DT	
OVER-RIDE SITE/LAT/EOD	
OVER-RIDE SITE/LAT/MORPH	
SEER TYPE OF FOLLOW-UP	
AGE RECODE <1 YEAR OLDS	
SITE RECODE	58
SITE RECODE WITH KAPOSI SARCOMA AND MESOTHELIOMA	
RECODE ICD-O-2 TO 9	
RECODE ICD-O-2 TO 10	
ICCC SITE RECODE ICD-O-2	
SEER MODIFIED ICCC SITE RECODE ICD-O-2	60
ICCC SITE RECODE ICD-O-3	
ICCC SITE RECODE EXTENDED ICD-O-3	
BEHAVIOR RECODE FOR ANALYSIS	
ICD-O CODING SCHEME	
HISTOLOGY RECODE—BROAD GROUPINGS	
HISTOLOGY RECODE—BRAIN GROUPINGS	
CS SCHEMA	
RACE RECODE (WHITE, BLACK, OTHER)	
RACE RECODE (W, B, AI, API)	
ORIGIN RECODE NHIA (HISPANIC, NON-HISP)	

TABLE OF CONTENTS

SEER HISTORIC STAGE A	69
AJCC STAGE 3 RD EDITION (1988-2003)	70
SEER MODIFIED AJCC STAGE 3 RD ED (1988-2003)	
SEER SUMMARY STAGE 1977	72
SEER SUMMARY STAGE 2000	72
NUMBER OF PRIMARIES	73
FIRST MALIGNANT PRIMARY INDICATOR	
STATE-COUNTY RECODE	73
SURVIVAL TIME RECODE	74
CAUSE OF DEATH TO SEER SITE RECODE	74
COD TO SITE REC KM	75
VITAL STATUS RECODE	75
IHS LINK	75
SUMMARY STAGE 2000 (1998+)	76
AYA SITE RECODE	
LYMPHOMA SUBTYPE RECODE	76
SEER CAUSE-SPECIFIC DEATH CLASSIFICATION	76

COMPUTER RECORD FORMAT

Item Name	Applicable	NAACCR Item #	Positions	Length
	Years			
Patient ID number		20	01-08	8
Registry ID		40	09-18	10
Marital Status at DX		150	19-19	1
Race/Ethnicity		160	20-21	2
Spanish/Hispanic Origin		190	22-22	1
NHIA Derived Hispanic Origin		191	23-23	1
Sex		220	24-24	1
Age at diagnosis		230	25-27	3
Year of Birth		240	28-31	4
Birth Place		250	32-34	3
Sequence NumberCentral		380	35-36	2
Month of diagnosis		390	37-38	2
Year of diagnosis		390	39-42	4
Primary Site		400	43-46	4
Laterality		410	47-47	1
Histology (92-00) ICD-O-2		420	48-51	4
Behavior (92-00) ICD-O-2		430	52-52	1
Histologic Type ICD-O-3		522	53-56	4
Behavior Code ICD-O-3		523	57-57	1
Grade		440	58-58	1
Diagnostic Confirmation		490	59-59	1
Type of Reporting Source		500	60-60	1
EOD—Tumor Size	1988-2003	780	61-63	3
EOD—Extension	1988-2003	790	64-65	2
EOD—Extension Prost Path	1985-2003	800	66-67	2
EOD—Lymph Node Involv	1988-2003	810	68-68	1
Regional Nodes Positive	1988+	820	69-70	2
Regional Nodes Examined	1988+	830	71-72	2
EOD—Old 13 Digit	1973-1982	840	73-85	13
EOD—Old 2 Digit	1973-1982	850	86-87	2
EOD—Old 4 Digit	1983-1987	860	88-91	4
Coding System for EOD	1973-2003	870	92-92	1
Tumor Marker 1	1990-2003	1150	93-93	1
Tumor Marker 2	1990-2003	1160	94-94	1
Tumor Marker 3	1998-2003	1170	95-95	1
CS Tumor Size	2004+	2800	96-98	3
CS Extension	2004+	2810	99-100	2
CS Lymph Nodes	2004+	2830	101-102	2
CS Mets at Dx	2004+	2850	103-104	2
CS Site-Specific Factor 1	2004+	2880	105-107	3
CS Site-Specific Factor 2	2004+	2890	108-110	3

COMPUTER RECORD FORMAT

	Applicable	NA A CCD II	D 111	
Item Name	Years	NAACCR Item #	Positions	Length
CS Site-Specific Factor 3	2004+	2900	111-113	3
CS Site-Specific Factor 4	2004+	2910	114-116	3
CS Site-Specific Factor 5	2004+	2920	117-119	3
CS Site-Specific Factor 6	2004+	2930	120-122	3
Derived AJCC T	2004+	2940	123-124	2
Derived AJCC N	2004+	2960	125-126	2
Derived AJCC M	2004+	2980	127-128	2
Derived AJCC Stage Group	2004+	3000	129-130	2
Derived SS1977	2004+	3010	131-131	1
Derived SS2000	2004+	3020	132-132	1
Derived AJCC—Flag	2004+	3030	133-133	1
Derived SS1977—Flag	2004+	3040	134-134	1
Derived SS2000—Flag	2004+	3050	135-135	1
CS Version 1 st	2004+	2935	136-141	6
CS Version Latest	2004+	2936	142-147	6
RX Summ—Surg Prim Site	1998+	1290	148-149	2
RX Summ—Scope Reg LN Sur	2003+	1292	150-150	1
RX Summ—Surg Oth Reg/Dis	2003+	1294	151-151	1
RX Summ—Reg LN Examined	1998-2002	1296	152-153	2
RX Summ—Reconstruct 1st	1998-2002	1330	154-154	1
Reason for no surgery		1340	155-155	1
RX Summ—Radiation		1360	156-156	1
RX Summ—Rad to CNS	1988-1997	1370	157-157	1
RX Summ—Surg / Rad Seq		1380	158-158	1
RX Summ—Surgery Type	1973-1997	1640	159-160	2
RX Summ—Surg Site 98-02	1998-2002	1646	161-162	2
RX Summ—Scope Reg 98-02	1998-2002	1647	163-163	1
RX Summ—Surg Oth 98-02	1998-2002	1648	164-164	1
SEER Record Number		2190	165-166	2
Over-ride age/site/morph		1990	167-167	1
Over-ride seqno/dxconf		2000	168-168	1
Over-ride site/lat/seqno		2010	169-169	1
Over-ride surg/dxconf		2020	170-170	1
Over-ride site/type		2030	171-171	1
Over-ride histology		2040	172-172	1
Over-ride report source		2050	173-173	1
Over-ride ill-define site		2060	174-174	1
Over-ride Leuk, Lymph		2070	175-175	1
Over-ride site/behavior		2071	176-176	1
Over-ride site/eod/dx dt		2072	177-177	1
Over-ride site/lat/eod		2073	178-178	1

COMPUTER RECORD FORMAT

Item Name	Applicable	NAACCR Item #	Positions	Length
	Years			
Over-ride site/lat/morph		2074	179-179	1
SEER Type of Follow-up		2180	181-181	1
Age Recode <1 Year olds		N/A	183-184	2
Site Recode		N/A	185-189	5
Site Rec with Kaposi and Mesothelioma		N/A	190-194	5
Recode ICD-O-2 to 9		N/A	195-198	4
Recode ICD-O-2 to 10		N/A	199-202	4
ICCC site recode ICD-O-2		N/A	203-205	3
SEER modified ICCC site recode ICD-O-2		N/A	206-208	3
ICCC site recode ICD-O-3		N/A	209-211	3
ICCC site recode extended ICD-O-3		N/A	212-214	3
Behavior Recode for Analysis		N/A	215-215	1
ICD-O Coding Scheme		N/A	216-216	1
Histology Recode—Broad Groupings		N/A	217-218	2
Histology Recode—Brain Groupings		N/A	219-220	2
CS Schema		N/A	221-222	2
Race recode (White, Black, Other)		N/A	223-223	1
Race recode (W, B, AI, API)		N/A	224-224	1
Origin recode NHIA (Hispanic, Non-Hisp)		N/A	225-225	1
SEER historic stage A		N/A	226-226	1
AJCC stage 3 rd edition (1988-2003)		N/A	227-228	2
SEER modified AJCC Stage 3 rd ed (1988-2003)		N/A	229-230	2
SEER Summary Stage 1977 (1995-2000)	1995-2000	N/A	231-231	1
SEER Summary Stage 2000 (2001-2003)	2001-2003	N/A	232-232	1
Number of primaries		N/A	233-234	2
First malignant primary indicator		N/A	235-235	1
State-county recode		N/A	236-240	5
Survival time recode		N/A	241-244	4
Cause of Death to SEER site recode		N/A	245-249	5
COD to site rec KM		N/A	250-254	5
Vital Status recode		N/A	255-255	1
IHS Link		192	258-258	1
Summary stage 2000 (1998+)	1998+	N/A	259-259	1
AYA site recode		N/A	260-261	2
Lymphoma subtype recode		N/A	262-263	2
SEER Cause-Specific Death Classification		N/A	264-264	1

PATIENT ID NUMBER

NAACCR Item #: 20

SEER*Stat Name: Patient ID

Item Length: 8

Field Description: The participating SEER registry generates a unique number and assigns that

number to one patient. The SEER registry will assign this same number to

all of the patient's subsequent tumors (records).

REGISTRY ID

NAACCR Item #: 40

SEER*Stat Name: SEER Registry

Item Length: 10

Field Description: A unique code assigned to each participating SEER registry. The number

identifies the registry sending the record and what population the data are

based on.

Codes

San Francisco-Oakland SMSA (1973)
Connecticut (1973)
Metropolitan Detroit (1973)
Hawaii (1973)
Iowa (1973)
New Mexico (1973)
Seattle (Puget Sound) (1974)
Utah (1973)
Metropolitan Atlanta (1975)
Alaska*
San Jose-Monterey*
Los Angeles*
Rural Georgia*
Greater California (excluding SF, Los Angeles & SJ)**
Kentucky**
Louisiana**
New Jersey**

(Year in parentheses refers to first diagnosis year data reported to SEER.)

*Note: The incidence/yr1992 2007.sj la rg ak directory files contain cases for Alaska, San

Jose-Monterey, Los Angeles and Rural Georgia registries beginning in 1992. Cases have been collected by SEER for these registries prior to 1992 but have been excluded from

the SEER Research Data file.

**Note: The incidence/yr2000_2007.ca_ky_lo_nj directory files contain cases for Greater

California, Kentucky, Louisiana and New Jersey registries beginning in 2000. For the year 2005, only January through June diagnoses are included for Louisiana. The July through December incidence cases can be found in the yr2005.lo 2nd half directory.

MARITAL STATUS AT DX

NAACCR Item #: 150

SEER*Stat Name: Marital status at diagnosis

Item Length: 1

Field Description: This data item identifies the patient's marital status at the time of diagnosis

for the reportable tumor.

Codes

1	Single (never married)
2	Married (including common law)
3	Separated
4	Divorced
5	Widowed
9	Unknown

RACE / ETHNICITY

NAACCR Item #: N/A

SEER*Stat Name: Race/ethnicity

Item Length: 2

Field Description: This field is created from Race1 and the Indian Health Service (IHS) Link

variables from the NAACCR File Format. If Race1 is white and there is a positive IHS link, then Race/ethnicity is set to American Indian/Alaskan

Native, otherwise Race/Ethnicity is set to the Race1 value.

01	White
02	Black
03	American Indian, Aleutian, Alaskan Native or Eskimo (includes
	all indigenous populations of the Western hemisphere)
04	Chinese
05	Japanese
06	Filipino
07	Hawaiian
08	Korean (Effective with 1/1/1988 dx)
09	Asian Indian, Pakistani (Effective with 1/1/1988 dx)
10	Vietnamese (Effective with 1/1/1988 dx)
11	Laotian (Effective with 1/1/1988 dx)
12	Hmong (Effective with 1/1/1988 dx)
13	Kampuchean (including Khmer and Cambodian) (Effective with
	1/1/1988 dx)

14	Thai (Effective with 1/1/1994 dx)
20	Micronesian, NOS (Effective with 1/1/1991)
21	Chamorran (Effective with 1/1/1991 dx)
22	Guamanian, NOS (Effective with 1/1/1991 dx)
25	Polynesian, NOS (Effective with 1/1/1991 dx)
26	Tahitian (Effective with 1/1/1991 dx)
27	Samoan (Effective with 1/1/1991 dx)
28	Tongan (Effective with 1/1/1991 dx)
30	Melanesian, NOS (Effective with 1/1/1991 dx)
31	Fiji Islander (Effective with 1/1/1991 dx)
32	New Guinean (Effective with 1/1/1991 dx)
96	Other Asian, including Asian, NOS and Oriental, NOS
	(Effective with $1/1/1991 dx$)
97	Pacific Islander, NOS (Effective with 1/1/1991 dx)
98	Other
99	Unknown

SEER Participants San Francisco, San Jose-Monterey, and Los Angeles are permitted to use codes 14 and 20-97 for cases diagnosed after January 1, 1987. Greater California is permitted to use codes 14 and 20-97 for cases diagnosed after January 1, 1988. Other SEER participants may choose to recode cases diagnosed prior to 1991 using 14 and 20-97 if all cases in the following race codes are reviewed: 96 Other Asian; 97 Pacific Islander, NOS; 98 Other; and 99 unknown.

SPANISH / HISPANIC ORIGIN

NAACCR item #: 190

SEER*Stat Name: Spanish surname or origin

Item Length: 1

Field Description: This data item is used to identify patients with Spanish/Hispanic surname or

of Spanish origin. Persons of Spanish or Hispanic surname/origin may be of

any race.

0	Non-Spanish/Non-Hispanic
1*	Mexican (includes Chicano)
2*	Puerto Rican
3*	Cuban
4*	South or Central American (except Brazil)
5*	Other specified Spanish/Hispanic origin (includes European; excludes Dominican Republic)
6	Spanish, NOS; Hispanic, NOS; Latino, NOS (<i>There is evidence, other than surname or maiden name, that the person is Hispanic but he/she cannot be assigned to any of the categories 1-5</i>).
7**	Spanish surname only (effective with diagnosis on or after 1/1/1994) (The only evidence of the person's Hispanic origin is the surname or maiden name and there is no contrary evidence that the patient is not Hispanic.)
8	Dominican Republic (effective with diagnosis on or after 1/1/2005)
9	Unknown whether Spanish/Hispanic or not

^{*}Note: Code began to be used for 1988+ diagnoses. For cases prior to 1988 it was only used if the person also had a diagnosis of an independent primary after 1987.

^{**}Note:Code began to be used for 1994+ diagnoses. For cases prior to 1994 it was only used if the person also had a diagnosis of an independent primary after 1993.

NHIA DERIVED HISPANIC ORIGIN

NAACCR Item #: 191

SEER*Stat Name: NHIA Derived Hispanic Origin

Item Length: 1

Field Description: The NAACCR Hispanic Identification Algorithm (NHIA) is a computerized

algorithm that uses a combination of variables to directly or indirectly

classify cases as Hispanic for analytic purposes.

Codes

0	Non-Spanish-Hispanic-Latino
1	Mexican
2	Puerto Rican
3	Cuban
4	South or Central American excluding Brazil
5	Other specified Spanish/Hispanic Origin including Europe
6	Spanish/Hispanic/Latino, NOS
7	NHIA Surname Match Only
8	Dominican Republic

SEX

NAACCR Item #: 220 SEER*Stat Name: Sex

Item Length: 1

Field Description: This data item identifies the sex of the patient at diagnosis.

Codes

1	Male
2	Female

AGE AT DIAGNOSIS

NAACCR Item #: 230

SEER*Stat Name: Age at diagnosis

Item Length: 3

Field Description: This data item represents the age of the patient at diagnosis for this cancer.

The code is three digits and represents the patient's actual age in years.

000-130	Actual age in years
999	Unknown age

BIRTHDATE—YEAR

NAACCR Item #: 240

SEER*Stat Name: Year of birth

Item Length: 4

Field Description:

Codes

1850-YYYY	Patient's year of birth
9999	Unknown year of birth

BIRTHPLACE

NAACCR Item #: 250

SEER*Stat Name: Place of birth

Item Length: 3

Field Description: See the following link for a list of SEER birthplace codes and definitions.

http://seer.cancer.gov/manuals/2004Revision%201/SPM AppendixB r1.pdf

SEQUENCE NUMBER--CENTRAL

NAACCR Item #: 380

SEER*Stat Name: Sequence number

Item Length: 2

Field Description: Sequence Number-Central describes the number and sequence of all

reportable malignant, in situ, benign, and borderline primary tumors, which occur over the lifetime of a patient. The sequence number may change over the lifetime of the patient. If an individual previously diagnosed with a single reportable malignant neoplasm is subsequently diagnosed with a second reportable malignant neoplasm, the sequence code for the first

neoplasm changes from 00 to 01.

This sequence number counts all tumors that were reportable in the year they were diagnosed even if the tumors occurred before the registry existed, or before the registry participated in the SEER Program. The purpose of sequencing based on the patient's *lifetime* is to truly identify the patients for survival analysis who only had one malignant primary in their lifetimes.

(Continued on next page)

(Continued from Sequence Number-Central)

Codes

In Situ/Malignant as Federally Required based on Diagnosis Year

00	One primary only in the patient's lifetime
01	First of two or more primaries
02	Second of two or more primaries
	(Actual number of this primary)
35	Thirty-fifth of thirty-five or more primaries
99	Unspecified or unknown sequence number of Federally required in situ or malignant tumors. Sequence number 99 can be used if there is a malignant tumor and its sequence
	number is unknown. (If there is known to be more than one malignant tumor, then the
	tumors must be sequenced.)

Non-malignant Tumor as Federally Required based on Diagnosis Year

60	Only one non-malignant tumor or central registry-defined neoplasm
61	First of two or more non-malignant tumors or central registry-defined neoplasms
62	Second of two or more non-malignant tumors or central registry-defined neoplasms
87	Twenty-seventh of twenty-seven
88	Unspecified or unknown sequence number of non-malignant tumor or central-registry defined neoplasms. (Sequence number 88 can be used if there is a non-malignant tumor and its sequence number is unknown. If there is known to be more than one non-malignant tumor, then the tumors must be sequenced.)
98	Cervix carcinoma in situ (CIS/CIN III, Diagnosis Years 1996-2002)

MONTH OF DIAGNOSIS

NAACCR Item #: 390

SEER*Stat Name: Month of diagnosis

Item Length: 2

Field Description: The month of diagnosis is the month the tumor was first diagnosed by a

recognized medical practitioner, whether clinically or microscopically confirmed. For analysis purposes, months coded to 99 (unknown) have been

replaced with values 01 through 12.

 $\frac{\text{Allowable values}}{\text{MM} = 01 - 12}$

YEAR OF DIAGNOSIS

NAACCR Item #: 390

SEER*Stat Name: Year of diagnosis

Item Length: 4

Field Description: The year of diagnosis is the year the tumor was first diagnosed by a

recognized medical practitioner, whether clinically or microscopically

confirmed.

Allowable values

YYYY = 1973 - forward

PRIMARY SITE

NAACCR Item #: 400

SEER*Stat Name: Primary Site

Item Length: 4

Field Description: This data item identifies the site in which the primary tumor originated. See

the *International Classification of Diseases for Oncology*, Third Edition (ICD-O-3) for topography codes. The decimal point is eliminated.

Cases diagnosed 1977-1991 were coded using the International

Classification of Diseases for Oncology, 1976 Edition (ICD-O-1976). Prior

to 1977 diagnoses, cases were coded using the Manual of Tumor

Nomenclature and Coding, 1968 (MOTNAC).

All cases 1973-1991 were machine-converted to ICD-O-2 codes without

complete hand review.

LATERALITY

NAACCR Item #: 410

SEER*Stat Name: Laterality (1973+)

Item Length: 1

Field Description: Laterality describes the side of a paired organ or side of the body on which

the reportable tumor originated. Starting with cases diagnosed January 1, 2004 and later, laterality is coded for select invasive, benign, and borderline

primary intracranial and CNS tumors.

See $\underline{\text{http://seer.cancer.gov/manuals/primsite.laterality.pdf}} \text{ for a list of sites for }$

which SEER requires information on laterality.

Codes

0 Not a paired site

- 1 | Right: origin of primary
- 2 Left: origin of primary
- 3 Only one side involved, right or left origin unspecified
- 4 | Bilateral involvement, lateral origin unknown; stated to be single primary
 - Both ovaries involved simultaneously, single histology
 - Bilateral retinoblastomas
 - Bilateral Wilms's tumors
- 9 | Paired site, but no information concerning laterality; midline tumor

HISTOLOGY (92-00) ICD-O-2

NAACCR Item #: 420

SEER*Stat Name: Histology (92-00) ICD-O-2

Item Length: 4

Field Description: NOTE: ALL CASES DIAGNOSED 1973-91 HAVE BEEN CONVERTED

TO THE INTERNATIONAL CLASSIFICATION OF DISEASES FOR

ONCOLOGY, SECOND EDITION (ICD-O-2, 1992).

The SEER program has used several different, but related, coding systems for morphology over time. One should be extremely careful when doing any analysis of trends related to morphology. It is suggested that these analyses start with diagnoses no earlier than 1977 and that special attention be paid to the changes for 1986-91 cases due to the use of the *International*

 ${\it Classification\ of\ Disease\ for\ Oncology,\ Field\ Trial\ Edition,\ March\ 1988\ and}$

for 1992+ cases due to the use of ICD-O-2.

Analyses of morphology data are usually limited to microscopically

confirmed cases only.

(Continued on next page)

(Continued from HISTOLOGY (92-00) ICD-O-2)

HISTOLOGY CODING

FOR CASES DIAGNOSED 1973-85:

Histologic types are defined in the morphology section of the *International Classification of Diseases for Oncology*, 1976 Edition (ICD-O, 1976). However prior to the introduction of ICD-O, 1976, morphology was coded using the *Manual of Tumor Nomenclature and Coding*, 1968 (MOTNAC). With the introduction of ICD-O, 1976, all cases previously coded using MOTNAC were machine converted without hand review using the conversion table, *Conversion of Morphology Sections (neoplasms) of 1968 Manual of Tumor Nomenclature and Coding (MOTNAC) and 1965 Systematized Nomenclature of Pathology (SNOP) to 1976 International Classification of Diseases for Oncology*, developed by Constance Percy. The morphology codes of ICD-O, 1976, are more specific than those of MOTNAC. Thus, less detailed information on morphology is available for cases diagnosed 1973-76. For example, when using MOTNAC large cell carcinoma is included with carcinoma, not otherwise specified (NOS); when using ICD-O, 1976, large cell carcinoma is a separate entity having its own code. All have been machine converted to ICD-O-2.

FOR CASES DIAGNOSED 1973-85:

In addition, the following special morphology codes were used by the SEER Program:

Breast — All years

8522/3	Infiltrating duct carcinoma and lobular carcinoma
8523/3	Infiltrating duct carcinoma and lobular carcinoma in situ
8524/3	Intraductal carcinoma and lobular carcinoma
8522/2	Intraductal carcinoma and lobular carcinoma in situ
8543/3	Paget's disease with intraductal carcinoma

All sites — Introduced for coding in approximately 1982

9616/3	Lennert's lymphoma
9624/3	Malignant lymphoma, large cell, cleaved, diffuse
9634/3	Malignant lymphoma, large cell, non-cleaved, diffuse
9723/3	True histiocytic lymphoma

(Continued on next page)

(Continued from HISTOLOGY (92-00) ICD-O-2)

FOR CASES DIAGNOSED 1986-91:

Histologic types are defined in the morphology section of the *International Classification of Diseases for Oncology, Field Trial Edition, 1986* (ICD-O FT). (This volume is no longer available. It was replaced by the *International Classification of Diseases for Oncology, Field Trial Edition, March 1988* (ICD-O FT 1988). Pages i-vi, 23 of the latter volume list the differences between the two Field Trials, present a summary of the changes to ICD-O, 1976, and define the symbols used in the morphology section. These were converted to ICD-O-2.

FOR CASES DIAGNOSED 1992-2000:

Histologic types are defined in the morphology section of ICD-O-2. See pages 137+ in ICD-O-2 for additions and changes.

FOR CASES DIAGNOSED AFTER 2000:

All cases diagnosed after 2000 were converted from ICD-O-3 to ICD-O-2.

BEHAVIOR (92-00) ICD-O-2

NAACCR Item #: 430

SEER*Stat Name: Behavior code ICD-O-2

Item Length: 1

Field Description: Behavior codes are also defined in ICD-O-2, 1992.

Note: For bladder only, all in situs (/2) are converted to invasives (/3) before

inclusion on this file.

Cervix in situ not required after 1995.

FOR CASES DIAGNOSED AFTER 2000:

All cases diagnosed after 2000 were converted from ICD-O-3 to ICD-O2.

HISTOLOGIC TYPE ICD-0-3

NAACCR Item #: 522

SEER*Stat Name: Histologic Type ICD-O-3

Item Length: 4

Field Description: The data item Histologic Type describes the microscopic composition of

cells and/or tissue for a specific primary. The tumor type or histology is a basis for staging and determination of treatment options. It affects the prognosis and course of the disease. The *International Classification of Diseases for Oncology*, Third Edition (ICD-O-3) is the standard reference for

coding the histology for tumors diagnosed in 2001 and later.

All ICD-O-2 histologies for 1973-2000 were converted to ICD-O-3.

BEHAVIOR CODE ICD-O-3

NAACCR Item #: 523

SEER*Stat Name: Behavior code ICD-O-3 (1973+)

Item Length: 1

Field Description: SEER requires registries to collect malignancies with in situ /2 and malignant

/3 behavior codes as described in ICD-O-3. SEER requires registries to collect benign /0 and borderline /1 intracranial and CNS tumors for cases diagnosed on or after 1/1/2004. Behavior is the fifth digit of the morphology code after the slash (/). See ICD-O-3 (page 66) for a discussion of the

behavior code.

Codes

0	Benign (Reportable for intracranial and CNS sites only)
	Uncertain whether benign or malignant, borderline malignancy, low
1	malignant potential, and uncertain malignant potential (Reportable for
	intracranial and CNS sites only)
2	Carcinoma in situ; intraepithelial; noninfiltrating; noninvasive
3	Malignant, primary site (invasive)

All ICD-O-2 behaviors for 1973-2000 were converted to ICD-O-3.

GRADE

NAACCR Item #: 440 SEER*Stat Name: Grade

Item Length: 1

Field Description: Grading and differentiation codes of 1-4, 9 are defined in ICD-O-2; 1992. Grade

information may be incomplete for cases diagnosed before 1977.

In the early 1980's, additional codes specifying T-cell, B-cell, or null cell involvement in lymphomas and leukemias (histologies M9590-9940) were

introduced by SEER. Because the reporting requirements and medical terminology have changed over time, care should be exercised when analyzing this information.

Codes

1	Grade I; grade i; grade 1; well differentiated; differentiated, NOS
2	Grade II; grade ii; grade 2; moderately differentiated; moderately differentiated; intermediate differentiation
3	Grade III; grade iii; grade 3; poorly differentiated; differentiated
4	Grade IV; grade iv; grade 4; undifferentiated; anaplastic
5	T-cell; T-precursor
6	B-cell; Pre-B; B-Precursor
7	Null cell; Non T-non B;
8	N K cell (natural killer cell)
9	cell type not determined, not stated or not applicable

DIAGNOSTIC CONFIRMATION

NAACCR Item #: 490

SEER*Stat Name: Diagnostic Confirmation

Item Length: 1

Field Description: This data item records the best method used to confirm the presence of the

cancer being reported. The data item is not limited to the confirmation at the time of diagnosis; it is the best method of confirmation during the entire

course of the disease.

Codes

Microscopically Confirmed

1	Positive histology
2	Positive cytology
4	Positive microscopic confirmation, method not specified

(Continued on next page)

(Continued from Diagnostic Confirmation)

Not Microscopically Confirmed

- 5 Positive laboratory test/marker study
- 6 Direct visualization without microscopic confirmation
- Radiology and other imaging techniques without microscopic confirmation
- 8 Clinical diagnosis only (other than 5, 6, or 7)

Confirmation Unknown

9 Unknown whether microscopically confirmed; death certificate only

TYPE OF REPORTING SOURCE

NAACCR Item #: 500

SEER*Stat Name: Type of Reporting Source

Item Length: 1

Field Description: The Type of Reporting Source identifies the source documents used to

abstract the case. This is not necessarily the original document that identified

the case; rather, it is the source that provided the best information.

- Hospital inpatient; Managed health plans with comprehensive, unified medical records (new code definition effective with diagnosis on or after 1/1/2006)
- 2 Radiation Treatment Centers or Medical Oncology Centers (hospital-affiliated or independent) (effective with diagnosis on or after 1/1/2006)
- 3 | Laboratory Only (hospital-affiliated or independent)
- 4 Physician's Office/Private Medical Practitioner (LMD)
- 5 Nursing/Convalescent Home/Hospice
- 6 Autopsy Only
- 7 Death Certificate Only
- 8 Other hospital outpatient units/surgery centers (effective with diagnosis on or after 1/1/2006)

EOD—TUMOR SIZE

NAACCR Item #: 780

SEER*Stat Name: EOD 10—size (1988-2003)

Item Length: 3

Field Description: This item is part of the 10-digit EOD (Item #779). It records the largest

dimension of the primary tumor in millimeters. Unknown size=999.

This field is only coded for cases diagnosed 1988-2003. See SEER Extent of

Disease, 1988: Codes and Coding Instructions, Third Edition for site-

specific codes and coding rules, at

http://seer.cancer.gov/manuals/EOD10Dig.pub.pdf.

EOD—EXTENSION

NAACCR Item #: 790

SEER*Stat Name: EOD 10—extent (1988-2003)

Item Length: 2

Field Description: This item codes the farthest documented extension of tumor away from the

primary site, either by contiguous extension or distant metastases.

Allowable values = 00-99.

This field is only coded for cases diagnosed 1988-2003. See SEER Extent of

Disease, 1988: Codes and Coding Instructions, Third Edition for site-

specific codes and coding rules, at

http://seer.cancer.gov/manuals/EOD10Dig.pub.pdf.

EOD—EXTENSION PROST PATH

NAACCR Item #: 800

SEER*Stat Name: EOD 10—Prostate path ext (1995-2003)

Item Length: 2

Field Description: This is an additional field for prostate cancer only to reflect information from

radical prostatectomy, effective with 1995 diagnoses. The field is left blank

for all other primaries. Allowable values = 00-99.

This field is only coded for prostate cases diagnosed 1995-2003. See *SEER Extent of Disease*, 1988: Codes and Coding Instructions, Third Edition for

site-specific codes and coding rules, at

http://seer.cancer.gov/manuals/EOD10Dig.pub.pdf.

EOD-LYMPH NODE INVOLV

NAACCR Item #: 810

SEER*Stat Name: EOD 10—nodes (1988-2003)

Item Length: 1

Field Description: This item records the highest specific lymph node chain that is involved by

the tumor. Allowable values = 0-9.

This field is only coded for cases diagnosed 1988-2003. See SEER Extent of

Disease, 1988: Codes and Coding Instructions, Third Edition for site-

specific codes and coding rules, at

http://seer.cancer.gov/manuals/EOD10Dig.pub.pdf.

REGIONAL NODES POSITIVE

NAACCR Item #: 820

SEER*Stat Name: Regional nodes positive (1988+)

Item Length: 2

Field Description: Records the exact number of regional lymph nodes examined by the

pathologist that were found to contain metastases.

00	All nodes examined are negative
01-89	Exact number of nodes positive
90	90 or more nodes are positive
95	Positive aspiration of lymph node(s) was performed
97	Positive nodes are documented, but number is unspecified
98	No nodes were examined
99	Unknown whether nodes are positive; not applicable; not
	stated in patient record

REGIONAL NODES EXAMINED

NAACCR Item #: 830

SEER*Stat Name: Regional nodes examined (1988+)

Item Length: 2

Field Description: Records the total number of regional lymph nodes that were removed and

examined by the pathologist.

Codes 00 No nodes were examined 01-89 Exact number of nodes examined 90 90 or more nodes were examined 95 No regional nodes were removed, but aspiration of regional nodes was performed 96 Regional lymph node removal was documented as a sampling, and the number of nodes is unknown/not stated 97 Regional lymph node removal was documented as a dissection, and the number of nodes is unknown/not stated 98 Regional lymph nodes were surgically removed, but the number of lymph nodes is unknown/not stated and not documented as a sampling or dissection; nodes were examined, but the number is unknown 99 Unknown whether nodes were examined; not applicable or negative; not stated in patient record

EOD—OLD 13 DIGIT

NAACCR Item #: 840

SEER*Stat Name: Expanded EOD(1) - Expanded EOD (13)

Item Length: 13

Field Description: Detailed site-specific codes for EOD used by SEER for selected sites of

cancer for tumors diagnosed 1973-1982, except death-certificate-only cases.

For details, reference the following website:

http://seer.cancer.gov/manuals/historic/EOD_1977.pdf

EOD—OLD 2 DIGIT

NAACCR Item #: 850

SEER*Stat Name: 2-Digit NS EOD / 2-Digit SS EOD

Item Length: 2

Field Description: Site-specific codes for EOD used by SEER for tumors diagnosed from

January 1, 1973, to December 31, 1982, for cancer sites that did not have a

13-digit scheme. For details, reference the following website:

http://seer.cancer.gov/manuals/historic/EOD_1977.pdf

EOD—OLD 4 DIGIT

NAACCR Item #: 860

SEER*Stat Name: EOD 4 - size (first two digits)

EOD 4 - extent (third digit)

EOD 4 - nodes (fourth digit)

Item Length: 4

Field Description Codes for site-specific EOD used by SEER for tumors diagnosed from

January 1, 1983 to December 31, 1987 for all cancer sites. For details,

reference the following website:

http://seer.cancer.gov/manuals/historic/EOD_1984.pdf

CODING SYSTEM FOR EOD

NAACCR Item#: 870

SEER*Stat Name: Coding system—EOD (1973-2003)

Item Length: 1

Field Description: Indicates the type of SEER EOD code applied to the tumor.

0	2-Digit Nonspecific Extent of Disease (1973-82)
1	2-Digit Site-Specific Extent of Disease (1973-82)
2	13-Digit (expanded) Site Specific Extent of Disease (1973-82)
3	4-Digit Extent of Disease (1983-87)
4	10-Digit Extent of Disease, 1988 (1988-2003)
Blank	EOD coding scheme not applicable for cases diagnosed
	2004+.

TUMOR MARKER 1

NAACCR Item #: 1150

SEER*Stat Name: Tumor Marker 1 (1990-2003)

Item Length: 1

Field Description: This data item records prognostic indicators for breast cases (ERA 1990-

2003), prostate cases (PAP 1998-2003) and testis cases (AFP 1998-2003).

Codes

0	None Done
1	Positive
2	Negative
3	Borderline; undetermined whether
	positive or negative
8	Ordered, but results not in chart
9	Unknown or no information

For Testicular Cancer Cases (AFP 1998-2003)

0	None Done (SX)
2	Within normal limits (S0)
4	Range 1 (S1) <1,000 ng/ml
5	Range 2 (S2) 1,000 - 10,000 ng/ml
6	Range 3 (S3) >10,000 ng/ml
8	Ordered, but results not in chart
9	Unknown or no information

For All Other Cases

9 Not applicable

All sites except Breast diagnosed 1990-1997 are coded 9.

All diagnoses before January 1, 1990 are coded 9.

All diagnoses after 2003 are blank.

For Breast and Testis cases diagnosed 2004+, this information is collected using CS Site-Specific Factor 1 (NAACCR Item #2880). For Prostate cases diagnosed 2004+, information is no longer collected.

TUMOR MARKER 2

NAACCR Item #: 1160

SEER*Stat Name: Tumor Marker 2 (1990-2003)

Item Length: 1

Field Description: This data item records prognostic indicators for breast cases (PRA 1990-

2003), prostate cases (PSA 1998-2003), and testis cases (hCG 1998-2003).

Codes

0	None Done
1	Positive
2	Negative
3	Borderline; undetermined whether
	positive or negative
8	Ordered, but results not in chart
9	Unknown or no information

For Testicular Cancer Cases (hCG 1998-2003)

0	None Done (SX)
2	Within normal limits (S0)
4	Range 1 (S1) <5,000 mlU/ml
5	Range 2 (S2) 5,000 - 50,000 mlU/ml
6	Range 3 (S3) to >50,000 mlU/ml
8	Ordered, but results not in chart
9	Unknown or no information

For All Other Cases

9 Not applicable

All sites except Breast diagnosed 1990-1997 are coded 9.

All diagnoses before January 1, 1990 are coded 9.

All diagnoses after 2003 are blank.

For Breast, Prostate and Testis cases diagnosed 2004+, this information is collected using CS Site-Specific Factor 2 (NAACCR Item #2890).

TUMOR MARKER 3

NAACCR Item #: 1170

SEER*Stat Name: Tumor Marker 3 (1998-2003)

Item Length: 1

Field Description: This data item records prognostic indicators for testis cases (LDH 1998-

2003)

Codes

0	None Done (SX)
2	Within normal limits (S0)
4	Range 1 (S1) <1.5 x upper limit of normal
	for LDH assay
5	Range 2 (S2) 1.5 - 10 x upper limit of
	normal for LDH assay
6	Range 3 (S3) $>$ 10 x upper limit of normal
	for LDH assay
8	Ordered, results not in chart
9	Unknown or no information

All sites except testis diagnosed 1998-2003 are coded 9.

All diagnoses before 1998 are coded 9.

All diagnoses after 2003 are blank.

For Testis cases diagnosed 2004+, this information is collected using CS Site-Specific Factor 3 (NAACCR Item # 2900).

CS TUMOR SIZE

NAACCR Item #: 2800

SEER*Stat Name: CS tumor size (2004+)

Item Length: 3

Field Description: Records the largest dimension or diameter of the primary tumor, and is

always recorded in millimeters. To convert centimeters to millimeters, multiply the dimension by 10. This item is effective for cases diagnosed

2004+.

Codes

	_
000	Indicates no mass or no tumor found; for example, when a
	tumor of a stated primary site is not found, but the tumor has
	metastasized.
001-988	Exact size in millimeters
989	989 millimeters or larger
990	Microscopic focus or foci only; no size of focus is given
991	Described as less than 1 cm
992	Described as less than 2 cm
993	Described as less than 3 cm
994	Described as less than 4 cm
995	Described as less than 5 cm
999	Unknown; size not stated; not stated in patient record
888	Not applicable

See Appendix C of the SEER Program Coding and Staging Manual 2004, Revision 1 at http://seer.cancer.gov/tools/codingmanuals/historical.html for detailed codes and coding instructions.

Examples:

Mammogram shows 2.5 cm breast malignancy	Code as 025 (2.5 cm = 25 millimeters)
CT of chest shows 4 cm mass in RUL	Code as 040 (4 cm = 40 mm)
Thyroidectomy specimen yields 8 mm carcinoma	Code as 008
Prostate needle biopsy shows 0.6 mm carcinoma	Code as 001 (round up six-tenths of mm)

CS EXTENSION

NAACCR Item #: 2810

SEER*Stat Name: CS extension (2004+)

Item Length: 2

Field Description: Identifies contiguous growth (extension) of the primary tumor within the

organ of origin or its direct extension into neighboring organs. For certain sites such as ovary, discontinuous metastasis is coded in the CS Extension

field. This item is effective for cases diagnosed 2004+.

See Appendix C of the SEER Program Coding and Staging Manual 2004, Revision 1 at http://seer.cancer.gov/tools/codingmanuals/historical.html for

detailed codes and coding instructions.

CS LYMPH NODES

NAACCR Item #: 2830

SEER*Stat Name: CS lymph nodes (2004+)

Item Length: 2

Field Description: Identifies the regional lymph nodes involved with cancer at the time of

diagnosis. This item is effective for cases diagnosed 2004+.

See Appendix C of the SEER Program Coding and Staging Manual 2004, Revision 1 at http://seer.cancer.gov/tools/codingmanuals/historical.html for

detailed codes and coding instructions.

CS METS AT DX

NAACCR Item #: 2850

SEER*Stat Name: CS mets at dx (2004+)

Item Length: 2

Field Description: Identifies the distant site(s) of metastatic involvement at time of diagnosis.

This item is effective for cases diagnosed 2004+.

See Appendix C of the SEER Program Coding and Staging Manual 2004, Revision 1 at http://seer.cancer.gov/tools/codingmanuals/historical.html for

detailed codes and coding instructions.

CS SITE-SPECIFIC FACTOR 1

NAACCR Item #: 2880

SEER*Stat Name: CS site-specific factor 1 (2004+)

Item Length: 3

Field Description: Identifies additional information needed to generate stage, or prognostic

factors that have an effect on stage or survival. Site/Histology-specific codes

are used in addition to the general coding format below. This item is

effective for cases diagnosed 2004+.

See Appendix C of the SEER Program Coding and Staging Manual 2004, Revision 1 at http://seer.cancer.gov/tools/codingmanuals/historical.html for

site-specific codes and coding rules.

CS SITE-SPECIFIC FACTOR 2

NAACCR Item #: 2890

SEER*Stat Name: CS site-specific factor 2 (2004+)

Item Length: 3

Field Description: Identifies additional information needed to generate stage, or prognostic

factors that have an effect on stage or survival. Site/Histology-specific codes

are used in addition to the general coding format below. This item is

effective for cases diagnosed 2004+.

See Appendix C of the SEER Program Coding and Staging Manual 2004, Revision 1 at http://seer.cancer.gov/tools/codingmanuals/historical.html for

site-specific codes and coding rules.

CS SITE-SPECIFIC FACTOR 3

NAACCR Item #: 2900

SEER*Stat Name: CS site-specific factor 3 (2004+)

Item Length: 3

Field Description: Identifies additional information needed to generate stage, or prognostic

factors that have an effect on stage or survival. Site/Histology-specific codes

are used in addition to the general coding format below. This item is

effective for cases diagnosed 2004+.

See Appendix C of the SEER Program Coding and Staging Manual 2004, Revision 1 at http://seer.cancer.gov/tools/codingmanuals/historical.html for

site-specific codes and coding rules.

CS SITE-SPECIFIC FACTOR 4

NAACCR Item #: 2910

SEER*Stat Name: CS site-specific factor 4 (2004+)

Item Length: 3

Field Description: Identifies additional information needed to generate stage, or prognostic

factors that have an effect on stage or survival. Site/Histology-specific codes

are used in addition to the general coding format below. This item is

effective for cases diagnosed 2004+.

See Appendix C of the SEER Program Coding and Staging Manual 2004, Revision 1 at http://seer.cancer.gov/tools/codingmanuals/historical.html for

site-specific codes and coding rules.

CS SITE-SPECIFIC FACTOR 5

NAACCR Item #: 2920

SEER*Stat Name: CS site-specific factor 5 (2004+)

Item Length: 3

Field Description: Identifies additional information needed to generate stage, or prognostic

factors that have an effect on stage or survival. Site/Histology-specific codes

are used in addition to the general coding format below. This item is

effective for cases diagnosed 2004+.

See Appendix C of the SEER Program Coding and Staging Manual 2004, Revision 1 at http://seer.cancer.gov/tools/codingmanuals/historical.html for

site-specific codes and coding rules.

CS SITE-SPECIFIC FACTOR 6

NAACCR Item #: 2930

SEER*Stat Name: CS site-specific factor 6 (2004+)

Item Length: 3

Field Description: Identifies additional information needed to generate stage, or prognostic

factors that have an effect on stage or survival. Site/Histology-specific codes

are used in addition to the general coding format below. This item is

effective for cases diagnosed 2004+.

See Appendix C of the SEER Program Coding and Staging Manual 2004,

Revision 1 at http://seer.cancer.gov/tools/codingmanuals/historical.html for

site-specific codes and coding rules.

DERIVED AJCC T

NAACCR Item #: 2940

SEER*Stat Name: Derived AJCC T, 6th ed (2004+)

Item Length: 2

Field Description: This is the AJCC "T" component that is derived from CS coded fields, using the CS algorithm, effective with 2004+ diagnosis.

99	TX
00	T0
01	Ta
05	Tis
06	Tispu (Urethra only)
07	Tispd (Urethra only)
10	T1
11	T1mic
19	T1 NOS
12	T1a
13	T1a1
14	T1a2
15	T1b
16	T1b1
17	T1b2
18	T1c
20	T2
29	T2 NOS
21	T2a
22	T2b
23	T2c
30	T3
39	T3 NOS
31	T3a
32	T3b
33	T3c
40	T4
49	T4 NOS
41	T4a
42	T4b
43	T4c
44	T4d
88	Not applicable

DERIVED AJCC N

NAACCR Item #: 2960

SEER*Stat Name: Derived AJCC N, 6th ed (2004+)

Item Length: 2

Field Description: This is the AJCC "N" component that is derived from CS coded fields, using the CS algorithm, effective with 2004+ diagnosis.

99	NX
00	N0
09	N0 NOS
01	N0(i-)
02	N0(i+)
03	N0(mol-)
04	N0(mol+)
10	N1
19	N1 NOS
11	N1a
12	N1b
13	N1c
18	N1mi
20	N2
29	N2 NOS
21	N2a
22	N2b
23	N2c
30	N3
39	N3 NOS
31	N3a
32	N3b
33	N3c
88	Not applicable

DERIVED AJCC M

NAACCR Item #: 2980

SEER*Stat Name: Derived AJCC M, 6th ed (2004+)

Item Length: 2

Field Description: This is the AJCC "M" component that is derived from CS coded fields, using

the CS algorithm, effective with 2004+ diagnosis.

Codes

99	MX
00	M0
10	M1
11	M1a
12	M1b
13	M1c
19	M1 NOS
88	Not applicable

DERIVED AJCC STAGE GROUP

NAACCR Item #: 3000

SEER*Stat Name: Derived AJCC Stage Group, 6th ed (2004+)

Item Length: 2

Field Description: This is the AJCC "Stage Group" component that is derived from CS detailed

site-specific codes, using the CS algorithm, effective with 2004+ diagnosis.

00	Stage 0
01	Stage 0a
02	Stage 0is
10	Stage I
11	Stage I NOS
12	Stage IA
13	Stage IA1
14	Stage IA2
15	Stage IB
16	Stage IB1
17	Stage IB2
18	Stage IC
19	Stage IS
23	Stage ISA (lymphoma only)
24	Stage ISB (lymphoma only)
20	Stage IEA (lymphoma only)

21 Stage IEB (lymphoma only) 22 Stage IE (lymphoma only) 30 Stage II 31 Stage II NOS 32 Stage IIA 33 Stage IIB 34 Stage IIC 35 Stage IIEA (lymphoma only) 36 Stage IIEB (lymphoma only) 37 Stage IIE (lymphoma only) 38 Stage IISA (lymphoma only) 40 Stage IISB (lymphoma only) 41 Stage IISS (lymphoma only) 42 Stage IIESA (lymphoma only) 43 Stage IIES (lymphoma only) 50 Stage III 51 Stage III 51 Stage III 52 Stage IIIA 53 Stage IIIB 54 Stage IIIE 55 Stage IIIEA (lymphoma only) 56 Stage IIIEB (lymphoma only) 57 Stage IIIEB (lymphoma only) 58 Stage IIIEB (lymphoma only) 59 Stage IIISA (lymphoma only) 50 Stage IIISA (lymphoma only) 51 Stage IIISA (lymphoma only) 52 Stage IIISA (lymphoma only) 53 Stage IIISB (lymphoma only) 54 Stage IIISB (lymphoma only) 55 Stage IIIESA (lymphoma only) 56 Stage IIIESA (lymphoma only) 57 Stage IIIESA (lymphoma only) 58 Stage IIIESA (lymphoma only) 59 Stage IIIESA (lymphoma only) 60 Stage IIIESA (lymphoma only) 61 Stage IIIESA (lymphoma only) 62 Stage IIIESA (lymphoma only) 63 Stage IIIESA (lymphoma only) 64 Stage IIIESA (lymphoma only) 65 Stage IIIESA (lymphoma only) 66 Stage IIIESA (lymphoma only) 67 Stage IIIESA (lymphoma only) 68 Stage IIIESA (lymphoma only) 69 Stage IVA 60 Stage IVA 61 Stage IVA 62 Stage IVA 63 Stage IVA 63 Stage IVA 64 Stage IVA 65 Stage IVA 65 Stage IVA 66 Stage Unknown		
Stage II Stage II NOS Stage IIA Stage IIA Stage IIB Stage IIEA (lymphoma only) Stage IIEB (lymphoma only) Stage IIE (lymphoma only) Stage IISA (lymphoma only) Stage IISB (lymphoma only) Stage IISB (lymphoma only) Stage IISB (lymphoma only) Stage IISB (lymphoma only) Stage IIESB (lymphoma only) Stage IIESB (lymphoma only) Stage IIESB (lymphoma only) Stage IIESB (lymphoma only) Stage III Stage III NOS Stage IIIA Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV Stage IV Stage IV Stage IV Stage IV Stage IVC Not applicable Stage Occult	21	Stage IEB (lymphoma only)
Stage II NOS Stage IIA Stage IIB Stage IIEA (lymphoma only) Stage IIEB (lymphoma only) Stage IIEB (lymphoma only) Stage IISA (lymphoma only) Stage IISA (lymphoma only) Stage IISB (lymphoma only) Stage IISSA (lymphoma only) Stage IISSA (lymphoma only) Stage IIESA (lymphoma only) Stage IIESB (lymphoma only) Stage IIESB (lymphoma only) Stage III NOS Stage III NOS Stage IIIA Stage IIIEA (lymphoma only) Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISA (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV NOS Stage IV Stage IVB Stage IVB Stage IVB Stage IVC Not applicable Stage Occult	22	Stage IE (lymphoma only)
Stage IIA Stage IIB Stage IIC Stage IIEA (lymphoma only) Stage IIEB (lymphoma only) Stage IIE (lymphoma only) Stage IISA (lymphoma only) Stage IISB (lymphoma only) Stage IISB (lymphoma only) Stage IISSA (lymphoma only) Stage IIESA (lymphoma only) Stage IIESB (lymphoma only) Stage IIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage III Stage III Stage IIIA Stage IIIA Stage IIIEA (lymphoma only) Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV Stage IV Stage IV Stage IVB Stage IVB Stage IVC Not applicable Stage Occult	30	Stage II
Stage IIB Stage IIC Stage IIEA (lymphoma only) Stage IIEB (lymphoma only) Stage IIE (lymphoma only) Stage IISA (lymphoma only) Stage IISA (lymphoma only) Stage IISB (lymphoma only) Stage IISB (lymphoma only) Stage IIESA (lymphoma only) Stage IIESB (lymphoma only) Stage IIESB (lymphoma only) Stage IIES (lymphoma only) Stage III NOS Stage III Stage IIIA Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV Stage IV Stage IV Stage IV Stage IV Stage IVC Not applicable Stage Occult	31	Stage II NOS
Stage IIC Stage IIEA (lymphoma only) Stage IIEB (lymphoma only) Stage IIE (lymphoma only) Stage IISA (lymphoma only) Stage IISA (lymphoma only) Stage IISB (lymphoma only) Stage IISB (lymphoma only) Stage IIESA (lymphoma only) Stage IIESB (lymphoma only) Stage IIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage III Stage III Stage III Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV Stage IVA Stage IVA Stage IVC Not applicable Stage Occult	32	Stage IIA
Stage IIEA (lymphoma only) Stage IIEB (lymphoma only) Stage IIE (lymphoma only) Stage IISA (lymphoma only) Stage IISA (lymphoma only) Stage IISB (lymphoma only) Stage IISSA (lymphoma only) Stage IIESA (lymphoma only) Stage IIESB (lymphoma only) Stage IIESB (lymphoma only) Stage IIIS (lymphoma only) Stage III NOS Stage IIIA Stage IIIA Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV NOS Stage IV NOS Stage IVB Stage IVC Not applicable Stage Occult	33	Stage IIB
Stage IIEB (lymphoma only) Stage IIE (lymphoma only) Stage IISA (lymphoma only) Stage IISB (lymphoma only) Stage IISB (lymphoma only) Stage IIESA (lymphoma only) Stage IIESB (lymphoma only) Stage IIESB (lymphoma only) Stage IIESB (lymphoma only) Stage IIIS (lymphoma only) Stage III NOS Stage IIIA Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IVA Stage IVA Stage IVA Stage IVB Stage IVC Not applicable Stage Occult	34	Stage IIC
Stage IIE (lymphoma only) Stage IISA (lymphoma only) Stage IISB (lymphoma only) Stage IISB (lymphoma only) Stage IIESA (lymphoma only) Stage IIESA (lymphoma only) Stage IIESB (lymphoma only) Stage IIESB (lymphoma only) Stage IIIS (lymphoma only) Stage III NOS Stage IIIA Stage IIIC Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV Stage IV NOS Stage IVA Stage IVB Stage IVC Not applicable Stage Occult	35	Stage IIEA (lymphoma only)
Stage IISA (lymphoma only) Stage IISB (lymphoma only) Stage IIS (lymphoma only) Stage IIESA (lymphoma only) Stage IIESB (lymphoma only) Stage IIESB (lymphoma only) Stage IIIES (lymphoma only) Stage III NOS Stage IIIA Stage IIIA Stage IIIEA (lymphoma only) Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV NOS Stage IVA Stage IVA Stage IVB Not applicable Stage Occult	36	Stage IIEB (lymphoma only)
Stage IISB (lymphoma only) Stage IIS (lymphoma only) Stage IIESA (lymphoma only) Stage IIESB (lymphoma only) Stage IIESB (lymphoma only) Stage IIIS (lymphoma only) Stage III NOS Stage III NOS Stage IIIA Stage IIIEA (lymphoma only) Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV NOS Stage IVA Stage IVA Stage IVB Not applicable Stage Occult	37	Stage IIE (lymphoma only)
Stage IIS (lymphoma only) Stage IIESA (lymphoma only) Stage IIESB (lymphoma only) Stage IIES (lymphoma only) Stage IIIS (lymphoma only) Stage III NOS Stage IIIA Stage IIIB Stage IIIEA (lymphoma only) Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV Nos Stage IVA Stage IVB Stage IVB Stage IVC Not applicable Stage Occult	38	Stage IISA (lymphoma only)
Stage IIESA (lymphoma only) Stage IIESB (lymphoma only) Stage IIIES (lymphoma only) Stage IIII Stage III NOS Stage IIIIA Stage IIIB Stage IIIEA (lymphoma only) Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV Stage IV Stage IVA Stage IVA Stage IVB Stage IVC Not applicable Stage Occult	39	Stage IISB (lymphoma only)
Stage IIESB (lymphoma only) Stage IIIES (lymphoma only) Stage IIII Stage III NOS Stage IIIIA Stage IIIIA Stage IIIEA (lymphoma only) Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV NOS Stage IVA Stage IVA Stage IVB Not applicable Stage Occult	40	Stage IIS (lymphoma only)
Stage IIES (lymphoma only) Stage III Stage III NOS Stage IIIA Stage IIIB Stage IIIEA (lymphoma only) Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIES (lymphoma only) Stage IV Stage IV NOS Stage IVA Stage IVA Stage IVB Not applicable Stage Occult	41	Stage IIESA (lymphoma only)
Stage III Stage III NOS Stage IIIA Stage IIIA Stage IIIB Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV NOS Stage IVA Stage IVA Stage IVB Stage IVC Not applicable Stage Occult	42	Stage IIESB (lymphoma only)
Stage III NOS Stage IIIA Stage IIIB Stage IIIEA Stage IIIEA Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV NOS Stage IVA Stage IVA Stage IVA Stage IVC Not applicable Stage Occult	43	Stage IIES (lymphoma only)
Stage IIIA Stage IIIB Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV NOS Stage IVA Stage IVA Stage IVB Not applicable Stage Occult	50	Stage III
Stage IIIB Stage IIIC Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISS (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV NOS Stage IVA Stage IVA Stage IVB Not applicable Stage Occult	51	
Stage IIIC Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIEB (lymphoma only) Stage IIISA (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIES (lymphoma only) Stage IV Stage IV NOS Stage IVA Stage IVA Stage IVB Not applicable Stage Occult	52	Stage IIIA
Stage IIIEA (lymphoma only) Stage IIIEB (lymphoma only) Stage IIIE (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIES (lymphoma only) Stage IV Stage IV NOS Stage IVA Stage IVA Stage IVB Not applicable Stage Occult	53	Stage IIIB
Stage IIIEB (lymphoma only) Stage IIIE (lymphoma only) Stage IIISA (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIES (lymphoma only) Stage IV Stage IV NOS Stage IVA Stage IVA Stage IVB Not applicable Stage Occult	54	Stage IIIC
Stage IIIE (lymphoma only) Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIES (lymphoma only) Stage IV Stage IV NOS Stage IVA Stage IVA Stage IVB And Stage IVC Not applicable Stage Occult	55	Stage IIIEA (lymphoma only)
Stage IIISA (lymphoma only) Stage IIISB (lymphoma only) Stage IIISB (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV NOS Stage IV NOS Stage IVA Stage IVB A Stage IVC Not applicable Stage Occult	56	Stage IIIEB (lymphoma only)
Stage IIISB (lymphoma only) Stage IIIS (lymphoma only) Stage IIIESA (lymphoma only) Stage IIIESB (lymphoma only) Stage IIIESB (lymphoma only) Stage IV Stage IV Stage IV NOS Stage IVA Stage IVB A Stage IVC Not applicable Stage Occult	57	Stage IIIE (lymphoma only)
60 Stage IIIS (lymphoma only) 61 Stage IIIESA (lymphoma only) 62 Stage IIIESB (lymphoma only) 63 Stage IIIES (lymphoma only) 70 Stage IV 71 Stage IV NOS 72 Stage IVA 73 Stage IVB 74 Stage IVC 88 Not applicable 90 Stage Occult	58	Stage IIISA (lymphoma only)
61 Stage IIIESA (lymphoma only) 62 Stage IIIESB (lymphoma only) 63 Stage IIIES (lymphoma only) 70 Stage IV 71 Stage IV NOS 72 Stage IVA 73 Stage IVB 74 Stage IVC 88 Not applicable 90 Stage Occult	59	Stage IIISB (lymphoma only)
62 Stage IIIESB (lymphoma only) 63 Stage IIIES (lymphoma only) 70 Stage IV 71 Stage IV NOS 72 Stage IVA 73 Stage IVB 74 Stage IVC 88 Not applicable 90 Stage Occult	60	Stage IIIS (lymphoma only)
63 Stage IIIES (lymphoma only) 70 Stage IV 71 Stage IV NOS 72 Stage IVA 73 Stage IVB 74 Stage IVC 88 Not applicable 90 Stage Occult	61	Stage IIIESA (lymphoma only)
70 Stage IV 71 Stage IV NOS 72 Stage IVA 73 Stage IVB 74 Stage IVC 88 Not applicable 90 Stage Occult	62	Stage IIIESB (lymphoma only)
 71 Stage IV NOS 72 Stage IVA 73 Stage IVB 74 Stage IVC 88 Not applicable 90 Stage Occult 	63	Stage IIIES (lymphoma only)
 72 Stage IVA 73 Stage IVB 74 Stage IVC 88 Not applicable 90 Stage Occult 	70	Stage IV
 73 Stage IVB 74 Stage IVC 88 Not applicable 90 Stage Occult 	71	Stage IV NOS
 74 Stage IVC 88 Not applicable 90 Stage Occult 	72	Stage IVA
88 Not applicable 90 Stage Occult	73	Stage IVB
90 Stage Occult	74	Stage IVC
8	88	Not applicable
99 Stage Unknown	90	Stage Occult
	99	Stage Unknown

DERIVED SS1977

NAACCR Item #: 3010

SEER*Stat Name: Derived SS1977 (2004+)

Item Length: 1

Field Description: This item is the derived "SEER Summary Stage 1977" from the CS

algorithm, effective with 2004+ diagnosis.

Codes

0	In Situ
1	Localized
2	Regional, direct extension
3	Regional, lymph nodes only
4	Regional, extension and nodes
5	Regional, NOS
7	Distant
8	Not applicable
9	Unknown/Unstaged

DERIVED SS2000

NAACCR Item #: 3020

SEER*Stat Name: Derived SS2000 (2004+)

Item Length: 1

Field Description: This item is the derived "SEER Summary Stage 2000" from the CS

algorithm, effective with 2004+ diagnosis.

0	In Situ
1	Localized
2	Regional, direct extension
3	Regional, lymph nodes only
4	Regional, extension and nodes
5	Regional, NOS
7	Distant
8	Not applicable
9	Unknown/Unstaged

DERIVED AJCC—FLAG

NAACCR Item #: 3030

SEER*Stat Name: Derived AJCC—Flag (2004+)

Item Length: 1

Field Description: Flag to indicate whether the derived AJCC stage was derived from CS or

EOD codes.

Codes

1	AJCC Sixth Edition derived from Collaborative Staging Manual and Coding Instructions, Version 1.0
2	AJCC Sixth Edition derived from EOD (prior to 2004)
Blank	Not derived

DERIVED SS1977—FLAG

NAACCR Item #: 3040

SEER*Stat Name: Derived SS1977—Flag (2004+)

Item Length: 1

Field Description: Flag to indicate whether the derived SEER Summary Stage 1977 was derived

from CS or EOD codes.

1	SS1977 derived from Collaborative Staging Manual and
	Coding Instructions, Version 1.0
2	SS1977 derived from EOD (prior to 2004)
Blank	Not derived

DERIVED SS2000—FLAG

NAACCR Item #: 3050

SEER*Stat Name: Derived SS2000—Flag (2004+)

Item Length: 1

Field Description: Flag to indicate whether the derived SEER Summary Stage 2000 was derived

from CS or EOD codes.

Codes

1	SS2000 derived from Collaborative Staging Manual and Coding Instructions, Version 1.0
2	SS2000 derived from EOD (prior to 2004)
Blank	Not derived

CS VERSION 1ST

NAACCR Item #: 2935

SEER*Stat Name: CS version input (2004+)

Item Length: 6

Field Description: This item indicates the number of the version used to initially code CS fields.

The first two digits represent the major version number; the second two digits represent minor version changes; and, the last two digits represent even less significant changes, such as corrections of typographical errors that do

not affect coding or derivation of results.

CS VERSION LATEST

NAACCR Item #: 2936

SEER*Stat Name: CS version latest (2004+)

Item Length: 6

Field Description: This item indicates the number of the version of the CS used most recently to

derive the CS output fields. The first two digits represent the major version number; the second two digits represent minor version changes; and, the last two digits represent even less significant changes, such as corrections of typographical errors that do not affect coding or derivation of results.

RX SUMM—SURG PRIM SITE

NAACCR Item #: 1290

SEER*Stat Name: RX Summ--Surg Prim Site (1998+)

Item Length: 2

Field Description: Surgery of Primary Site describes a surgical procedure that removes and/or

destroys tissue of the primary site performed as part of the initial work-up or

first course of therapy.

See Appendix C of the SEER Program Coding and Staging Manual 2004, Revision 1 at http://seer.cancer.gov/tools/codingmanuals/historical.html for

detailed codes and coding instructions.

General Coding Structure

00	None; no surgical procedure of primary site; diagnosed at autopsy only
10-19	Site-specific codes. Tumor destruction; no pathologic specimen or unknown whether there is a pathologic specimen
20-80	Site-specific codes. Resection; pathologic specimen
90	Surgery, NOS. A surgical procedure to the primary site was done, but no information on the type of surgical procedure is provided.
98	Special codes for hematopoietic, reticuloendothelial, immunoproliferative, myeloproliferative diseases; ill-defined sites; and unknown primaries (See site-specific codes for the sites and histologies), except death certificate only
99	Unknown if surgery performed; death certificate only

For diagnosis years 1998-2002, SEER registries were required to convert field RX Summ—Surg Site 98-02 (NAACCR Item #1646) to RX Summ—Surg Prim Site.

RX SUMM—SCOPE REG LN SUR

NAACCR Item #: 1292

SEER*Stat Name: RX Summ--Scope Reg LN Sur (2003+)

Item Length: 1

Field Description: Scope of Regional Lymph Node Surgery describes the procedure of removal,

biopsy, or aspiration of regional lymph nodes performed during the initial

work-up or first course of therapy at all facilities.

Codes

0	No regional lymph nodes removed or aspirated; diagnosed
	at autopsy.
1	Biopsy or aspiration of regional lymph node, NOS
2	Sentinel lymph node biopsy [only]
3	Number of regional lymph nodes removed unknown, not
	stated; regional lymph nodes removed, NOS
4	1 to 3 regional lymph nodes removed
5	4 or more regional lymph nodes removed
6	Sentinel node biopsy and code 3, 4, or 5 at same time or
	timing not noted
7	Sentinel node biopsy and code 3, 4, or 5 at different times
9	Unknown or not applicable; death certificate only

RX SUMM-SURG OTH REG/DIS

NAACCR Item #: 1294

SEER*Stat Name: RX Summ--Surg Oth Reg/Dis (2003+)

Item Length: 1

Field Description: Surgical procedure of Other Site describes the surgical removal of distant

lymph node(s) or other tissue(s) or organ(s) beyond the primary site.

0	None; diagnosed at autopsy
1	Nonprimary surgical procedure performed
2	Nonprimary surgical procedure to other regional sites
3	Non-primary surgical procedure to distant lymph node(s)
4	Nonprimary surgical procedure to distant site
5	Combination of codes 2, 3, or 4
9	Unknown; death certificate only

RX SUMM-REG LN EXAMINED

NAACCR Item #: 1296

SEER*Stat Name: Num of regional lym nd exam (1998-2002)

Item Length: 2

Field Description: This data item records the number of regional lymph nodes examined in

conjunction with surgery performed as part of the first course of treatment at all facilities. This item is only available for cases diagnosed 1998-2002.

Codes

00	No regional lymph nodes examined	
01	One regional lymph node examined	
02	Two regional lymph nodes examined	
	(Actual number of lymph nodes examined)	
90	90 or more regional lymph nodes examined	
95	No regional lymph nodes examined	
96	Regional lymph node removal documented as sampling, and	
	number of lymph nodes unknown/not stated	
97	Regional lymph node removal documented as dissection, and	
	number of lymph nodes unknown/not stated	
98	Regional lymph nodes surgically removed, but number of lymph	
	nodes unknown/not stated and not documented as sampling or	
	dissection	
99	Unknown; not stated; death certificate-only	

RECONSTRUCTION-FIRST COURSE (1998-2002)

NAACCR Item #: 1330

SEER*Stat Name: First course of reconstruct (1998-2002)

Item Length: 1

Field Description: The SEER program collects information in this field only for breast cancer

and only for reconstruction begun as part of first course of treatment. This

item is only available for diagnosis years 1998-2002.

0	No reconstruction/restoration
1	Reconstruction, NOS (unknown if flap)
2	Implant; reconstruction WITHOUT flap
3	Reconstruction WITH flap, NOS
4	Latissimus dorsi flap
5	Abdominus recti flap
6	Flap, NOS plus implant
7	Latissimus dorsi flap plus implant
8	Abdominus recti plus implant
9	Unknown; not stated; death certificate only

REASON FOR NO SURGERY

NAACCR Item #: 1340

SEER*Stat Name: Reason no cancer-directed surgery

Item Length: 1

Field Description: This data item documents the reason that surgery was not performed on the

primary site.

Codes

0	Surgery performed
---	-------------------

No surgery

1*	Surgery not recommended	
2*	Contraindicated due to other conditions; Autopsy Only case	
5	Patient died before recommended surgery	
6	Unknown reason for no surgery	
7*	Patient or patient's guardian refused	

Unknown if surgery performed

8	Recommended, unknown if done
9	Unknown if surgery performed; Death Certificate Only case

^{*}Codes not used prior to 1988. Code '2' used only for Autopsy Only cases prior to 1988.

RX SUMM—RADIATION

NAACCR Item #: 1360 SEER*Stat Name: Radiation

Item Length: 1

Field Description: This data item indicates the method of radiation therapy performed as part of

the first course of treatment.

Codes

0	None; diagnosed at autopsy
1	Beam radiation
2	Radioactive implants
3	Radioisotopes
4	Combination of 1 with 2 or 3
5	Radiation, NOS – method or source not specified
6	Other radiation (1973-1987 cases only)
7	Patient or patient's guardian refused radiation therapy
8	Radiation recommended, unknown if administered
9	Unknown if radiation administered

RX SUMM—RAD TO CNS

NAACCR Item #: 1370

SEER*Stat Name: Radiation to Brain or CNS (1988-1997)

Item Length: 1

Field Description: This variable was only collected for years 1988-1997 for lung and leukemia

cases only. This data item codes for radiation given to the brain or central

nervous system at all facilities as part of the first course of therapy.

	None
1	Radiation Refused
7	Refused
8	Recommended, unknown if administered
9	Unknown

RX SUMM—SURG/RAD SEQ

NAACCR Item #: 1380

SEER*Stat Name: Radiation sequence with surgery

Item Length: 1

Field Description: This field records the order in which surgery and radiation therapies were

administered for those patients who had both surgery and radiation.

Codes

0	No radiation and/or surgery as defined above	
2	Radiation before surgery	
3	Radiation after surgery	
4	Radiation both before and after surgery	
5	Intraoperative radiation therapy	
6	Intraoperative radiation with other radiation	
	given before or after surgery	
9	Sequence unknown, but both surgery and	
	radiation were given	

RX SUMM-SURG TYPE

NAACCR Item #: 1640

SEER*Stat Name: Site specific surgery (1983-1997)

Item Length: 2

Field Description: The actual coding schemes for individual sites and time periods can be viewed at http://seer.cancer.gov/manuals/historic/AppendD.pdf. The discussion below summarizes the information available by site and time period.

> This field specifies information on surgery during first course of therapy whether it was cancer-directed or not. (Prior to 1988 SEER did not collect information on surgical procedures if not cancer-directed.) The Reason for No Cancer-directed Surgery field must be used to distinguish among no cancer-directed surgery performed; cancer-directed surgery recommended, unknown if performed; and unknown if cancer-directed surgery performed.

FOR CASES DIAGNOSED 1973-82:

All cases were coded using the following nonspecific scheme:

No Cancer-Directed Surgery/Unknown¹

00	No surgical procedure
09	Unknown if surgery done

(Continued on next page)

(Continued from RX SUMM-SURG TYPE)

Type of Cancer-Directed Surgery

90	Surgery, NOS

¹Code '09' must be used in conjunction with Reason for No Cancer-directed Surgery to distinguish "No cancer directed surgery" from "Unknown if cancer-directed surgery performed" and "Cancer-directed surgery recommended but unknown if given." Code '00' is only used for cases diagnosed only at autopsy.

FOR CASES DIAGNOSED 1983-87:

Detailed schemes were in place for the following sites:

ICD-O Codes	Primary Site
C16.0-C16.9	Stomach
C18.0-C18.9	Colon
C19.9, C20.9	Rectosigmoid, Rectum
C34.0-C34.9	Bronchus and Lung
C44.0-C44.9	Skin (melanomas only)
C50.0-C50.9	Breast
C53.0-C53.9	Cervix Uteri
C54.0-C54.9	Corpus Uteri
C56.9	Ovary
C61.9	Prostate
C67.0-C67.9	Bladder
C64.9, C65.9, C66.9	Kidney, Renal Pelvis, Ureter

All other sites are coded to the same nonspecific scheme used for 1973-82 cases (above).

FOR CASES DIAGNOSED 1988-1997:

In addition to the above sites, detailed schemes for the following sites were put into place:

ICD-O Codes	Primary Site
.C00.0-C14.8	Oral Cavity
C25.0-C25.9	Pancreas
C32.0-C32.9	Larynx
C42.2	Spleen
C41.0-C41.9	Connective tissue
C47.0-C47.9,C49.0-C49.9	Bone
C62.0-C62.9	Testis
C73.9	Thyroid
C77.0-C77.9	Lymph nodes

A general scheme was used for all other sites.

.

(Continued from RX SUMM-SURG TYPE)

FOR CASES DIAGNOSED 1998-2002:

Surgery information is collected in fields:

RX Summ—Surg Site 98-02 (NAACCR Item #1646)

RX Summ—Scope Reg 98-02 (NAACCR Item #1647)

RX Summ—Surg Oth 89-02 (NAACCR Item #1648

FOR CASES DIAGNOSED 2003+

Surgery information is collected in fields:

RX Summ—Surg Prim Site (NAACCR Item #1290)

RX SUmm—Scope Reg LN Sur (NAACCR Item #1292)

RX Summ—Surg Oth Reg/Dis (NAACCR Item #1294)

RX SUMM—SURG SITE 98-02

NAACCR Item #: 1646

SEER*Stat Name: Surgery of primary site (1998-2002)

Item Length: 2

Field Description: Site-specific codes for the type of surgery to the primary site performed as

part of the first course of treatment at all facilities for cases diagnosed 1998-

2002.

See http://seer.cancer.gov/manuals/historic/AppendC.pdf for a list of valid

codes.

RX SUMM—SCOPE REG 98-02

NAACCR Item #: 1647

SEER*Stat Name: Scope of reg lymph nd surg (1998-2002)

Item Length: 1

Field Description: This field describes the removal, biopsy or aspiration of regional lymph

node(s) at the time of surgery of the primary site or during a separate surgical

event at all facilities for cases diagnosed 1998-2002.

See http://seer.cancer.gov/manuals/historic/AppendC.pdf for a list of valid

codes.

RX SUMM—SURG OTH 98-02

NAACCR Item #: 1648

SEER*Stat Name: Surgery of oth reg/dis sites (1998-2002)

Item Length: 1

Field Description: This field records the removal of distant lymph nodes or other

tissue(s)/organ(s) beyond the primary site given at all facilities as part of the

first course of treatment for cases diagnosed 1998-2002.

See http://seer.cancer.gov/manuals/historic/AppendC.pdf for a list of valid

codes.

SEER RECORD NUMBER

NAACCR Item #: 2190

SEER*Stat Name: Record number

Item Length: 2

Field Description: The Record Number is a unique sequential number. The highest number for

each patient identifies the number of records that have been submitted to SEER for that particular patient. This data item is helpful in record linkage. The record number is generated by the computer system for each SEER submission. The record numbers are sequential starting with the number 01.

Codes

01 02	First (or only) record for the person Second record for the person
 nn	Last of nn records for person

OVER-RIDE AGE/SITE/MORPH

NAACCR Item #: 1990

SEER*Stat Name: Age-site edit override

Item Length: 1

Field Description: Codes

blank	Not reviewed
1	Reviewed: An unusual occurrence of a particular
	site/histology combination for a given age group has
	been reviewed.

OVER-RIDE SEQNO/DXCONF

NAACCR Item #: 2000

SEER*Stat Name: Sequence number-dx conf override

Item Length: 1

blank	Not reviewed
1	Reviewed: Multiple primaries of special sites in
	which at least one diagnosis has not been
	microscopically confirmed have been reviewed.

OVER-RIDE SIT/LAT/SEQNO

NAACCR Item #: 2010

SEER*Stat Name: Site-type-lat-seq override

Item Length: 1

Field Description: Codes

blank	Not reviewed
1	Reviewed: Multiple primaries of the same histology (3
	digit) in the same primary site group have been reviewed.

OVER-RIDE SURG/DXCONF

NAACCR Item #: 2020

SEER*Stat Name: Surgery-diagnostic conf override

Item Length: 1

Field Description: Codes

blank	Not reviewed
1	Reviewed: A patient who had (cancer-directed) surgery, but the tissue removed was not sufficient for microscopic
	confirmation.

OVER-RIDE SITE/TYPE

NAACCR Item #: 2030

SEER*Stat Name: Site-type edit override

Item Length: 1

blank	Not Reviewed
1	Reviewed: The coding of an unusual combination of
	primary site and histologic type has been reviewed.

OVER-RIDE HISTOLOGY

NAACCR Item #: 2040

SEER*Stat Name: Histology edit override

Item Length: 1

Field Description: Codes

blank	Not Reviewed
1	Unusual Histology behavior combination reviewed.
2	Unusual Diagnostic Confirmation/Behavior combination reviewed.
3	Both scenarios above reviewed

OVER-RIDE REPORT SOURCE

NAACCR Item #: 2050

SEER*Stat Name: Report source sequence override

Item Length: 1

Field Description: Codes

blank	Not reviewed
1	Reviewed: A second or subsequent primary with a reporting source
	of death certificate only has been reviewed and is indeed an
	independent primary.

OVER-RIDE ILL-DEFINE SITE

NAACCR Item #: 2060

SEER*Stat Name: Seq-ill-defined site override

Item Length: 1

blank	Not reviewed
1	Reviewed: A second or subsequent primary reported with an
	ill-defined primary site (C76.0-C76.8, C80.9) has been reviewed and
	is an independent primary.

OVER-RIDE LEUK, LYMPHOMA

NAACCR Item #: 2070

SEER*Stat Name: Leuk-Lymph dx confirmation override

Item Length: 1

Field Description:

Codes

blank	Not reviewed
1	Reviewed: A patient was diagnosed with leukemia or
	lymphoma and the diagnosis was not microscopically confirmed.

OVER-RIDE SITE/BEHAVIOR

NAACCR Item #: 2071

SEER*Stat Name: Site-behavior override

Item Length: 1

Field Description: The IF39 edit does not allow in situ cases of nonspecific sites, such as

gastrointestinal tract, NOS; uterus, NOS; female genital tract, NOS; male genital organs, NOS; and others. This over-ride indicates that the conflict

has been reviewed.

Codes

blank	Not reviewed
1	Reviewed: A patient has an in situ cancer of a nonspecific site
	and no further information about the primary site is available.

OVER-RIDE SITE/EOD/DX DT

NAACCR Item #: 2072

SEER*Stat Name: Site-EOD-dx date override

Item Length: 1

Field Description: The IF40 edit does not allow "localized" disease with non-specific sites, such

as mouth, NOS; colon, NOS (except histology 8220); bone, NOS; female genital system, NOS; male genital organs, NOS; and others. This over-ride

indicates that the conflict has been reviewed.

blank	Not reviewed
1	Reviewed: A patient had "localized" disease with a non-specific
	site and no further information about the primary site is available.

OVER-RIDE SITE/LAT/EOD

NAACCR Item #: 2073

SEER*Stat Name: Site-laterality-EOD override

Item Length: 1

Field Description: The IF41 edit for paired organs does not allow EOD to be specified as in situ,

localized, or regional by direct extension if laterality is coded as "bilateral, side unknown" or "laterality unknown." This over-ride indicates that the

conflict has been reviewed.

Codes

blank	Not reviewed
1	Reviewed: A patient had laterality coded non-specifically and
	EOD coded specifically.

OVER-RIDE SITE/LAT/MORPH

NAACCR Item #: 2074

SEER*Stat Name: Site-laterality-morph override

Item Length: 1

Field Description: The IF42 edit does not allow behavior code of "in situ" with non-specific

laterality codes. This over-ride indicates that the conflict has been reviewed.

blank	Not reviewed
1	Reviewed: A patient had behavior code of "in situ" and
	laterality is not stated as right: origin of primary; left: origin of
	primary; or only one side involved, right or left origin not
	specified.

SEER TYPE OF FOLLOW-UP

NAACCR Item #: 2180

SEER*Stat Name: Type of follow-up expected

Item Length: 1

Field Description: This item codes the type of follow-up expected for a SEER case.

Codes

	"Autopsy Only" or "Death Certificate Only" case
	Active follow up case
3	In situ cancer of the cervix uteri only
4	Case not originally in active follow up, but in active follow up now (San Francisco-Oakland only)

AGE RECODE <1 YEAR OLDS

NAACCR Item #: N/A

SEER*Stat Name: Age recode with <1 year olds

Item Length: 2

Field Description: To obtain five-year age groups that correspond to the population data,

combine codes 00 and 01.

00	Age 00
01	Ages 01-04
02	Ages 05-09
03	Ages 10-14
04	Ages 15-19
05	Ages 20-24
06	Ages 25-29
07	Ages 30-34
08	Ages 35-39
09	Ages 40-44
10	Ages 45-49
11	Ages 50-54
12	Ages 55-59
13	Ages 60-64
14	Ages 65-69
15	Ages 70-74
16	Ages 75-79
17	Ages 80-84
18	Ages 85+
99	Unknown Age

SITE RECODE

NAACCR Item #: N/A

SEER*Stat Name: Site recode

Item Length: 5

Field Description: For publications, SEER has defined major site groups based on primary site

and ICD-O-3 morphology.

See http://seer.cancer.gov/siterecode/icdo3_d01272003 for SEER Site

Recode Definitions.

SITE RECODE WITH KAPOSI SARCOMA AND MESOTHELIOMA

NAACCR Item #: N/A

SEER*Stat Name: Site rec with Kaposi and mesothelioma

Item Length: 5

Field Description: For publications, SEER has defined major site groups based on primary site

and ICD-O-3 morphology including Kaposi Sarcoma and mesothelioma.

See http://seer.cancer.gov/siterecode/icdo3_d01272003/ for SEER Site

recode with Kaposi Sarcoma and mesothelioma definitions.

RECODE ICD-O-2 TO 9

NAACCR Item #: N/A

SEER*Stat Name: Recode ICD-O-2 to 9

Item Length: 4

Field Description: The primary site and morphology as coded in ICD-O-2 are converted to ICD-

9 codes using the Conversion of Malignant Neoplasms by Topography and Morphology from the International Classification of Disease for Oncology, Second Edition (ICD-0-2) to International Classification of Diseases, 9th Revision (ICD-9) and the International Classification of Diseases, 9th Revision, Clinical Modification, Fourth Edition (ICD-9-CM) 4th Ed., 1992

edited by Constance Percy.

RECODE ICD-O-2 TO 10

NAACCR Item #: N/A

SEER*Stat Name: Recode ICD-O-2 to 10

Item Length: 4

Field Description: The primary site and morphology as coded in ICD-O-2 are converted to ICD-

10 codes using the Conversion of Malignant Neoplasms by Topography and Morphology from the International Classification of Disease for Oncology, Second Edition (ICD-O-2) to International Classification of Diseases and Related Health Problems, 10th Revision, 1998 edited by Constance Percy.

ICCC SITE RECODE ICD-O-2

NAACCR Item #: N/A

SEER*Stat Name: ICCC site recode ICD-O-2

Item Length: 3

Field Description: For publications, the International Classification of Childhood Cancer

(ICCC) has been defined based on primary site and ICD-O-2 morphology.

See http://seer.cancer.gov/iccc/iarciccc.html for ICCC site recode definitions.

SEER MODIFIED ICCC SITE RECODE ICD-O-2

NAACCR Item #: N/A

SEER*Stat Name: SEER modified ICCC site recode ICD-O-2

Item Length: 3

Field Description: For publications, SEER has modified the International Classification of

Childhood Cancer (ICCC).

See http://seer.cancer.gov/ICCC/seericcc.html for SEER modified ICCC site

recode definitions.

ICCC SITE RECODE ICD-O-3

NAACCR Item #: N/A

SEER*Stat Name: ICCC site recode ICD-O-3

Item Length: 3

Field Description: For publications, the International Classification of Childhood Cancer

(ICCC) has been defined based on primary site and ICD-O-3 morphology.

See http://seer.cancer.gov/iccc/iccc3.html for ICCC-3 main site recode

definitions.

ICCC SITE RECODE EXTENDED ICD-O-3

NAACCR Item #: N/A

SEER*Stat Name: ICCC site recode extended ICD-O-3

Item Length: 3

Field Description: For publications, the International Classification of Childhood Cancer

(ICCC) has been defined based on primary site and ICD-O-3 morphology.

See http://seer.cancer.gov/ICCC/iccc3_ext.html for ICCC-3 extended site

recode definitions.

BEHAVIOR RECODE FOR ANALYSIS

NAACCR Item #: N/A

SEER*Stat Name: Behavior recode for analysis

Item Length: 1

Field Description: For more information on the creation of this variable, see link below:

http://seer.cancer.gov/behavrecode/index.html

Codes

0	Benign
1	Borderline malignancy
2	In situ
3	Malignant
4	Only malignant in ICD-O-3
5	No longer reportable in ICD-O-3

ICD-O CODING SCHEME

NAACCR Item #: N/A

SEER*Stat Name: ICD-O coding scheme

Item Length: 1

2	Originally coded in ICD-O-2 (1973-2000)
3	Originally coded in ICD-O-3 (2001-2007)

HISTOLOGY RECODE—BROAD GROUPINGS

NAACCR Item #: N/A

SEER*Stat Name: Histology recode - broad groupings

Item Length: 2

Field Description:

00	8000-8009 : unspecified neoplasms
01	8010-8049 : epithelial neoplasms, NOS
02	8050-8089 : squamous cell neoplams
03	8090-8119 : basal cell neoplams
04	8120-8139: transitional cell papillomas and carcinomas
05	8140-8389 : adenomas and adenocarcinomas
06	8390-8429 : adnexal and skin appendage neoplams
07	8430-8439 : mucoepidermoid neoplasms
08	8440-8499 : cystic, mucinous and serous neoplams
09	8500-8549 : ductal and lobular neoplams
10	8550-8559 : acinar cell neoplasms
11	8560-8579 : complex epithelial neoplams
12	8580-8589 : thymic epithelial neoplams
13	8590-8679 : specialized gonadal neoplams
14	8680-8719 : paragangliomas and glumus tumors
15	8720-8799 : nevi and melanomas
16	8800-8809 : soft tissue tumors and sarcomas, NOS
17	8810-8839 : fibromatous neoplasms
18	8840-8849 : myxomatous neoplasms
19	8850-8889 : lipomatous neoplasms
20	8890-8929: myomatous neoplasms
21	8930-8999 : complex mixed and stromal neoplasms
22	9000-9039 : fibroepithelial neoplasms
23	9040-9049 : synovial-like neoplasms
24	9050-9059 : mesothelial neoplasms
25	9060-9099 : germ cell neoplasms
26	9100-9109 : trophoblastic neoplasms
27	9110-9119 : mesonephromas
28	9120-9169 : blood vessel tumors
29	9170-9179 : lymphatic vessel tumors
30	9180-9249 : osseous and chondromatous neoplasms

31	9250-9259 : giant cell tumors
32	9260-9269 : miscellaneous bone tumors (C40,C41)
33	9270-9349 : odontogenic tumors (C41)
34	9350-9379: miscellaneous tumors
35	9380-9489 : gliomas
36	9490-9529 : neuroepitheliomatous neoplasms
37	9530-9539: meningiomas
38	9540-9579 : nerve sheath tumors
39	9580-9589 : granular cell tumors & alveolar soft part sarcomas
40	9590-9599: malignant lymphomas, NOS or diffuse
41	9650-9669 : hodgkin lymphomas
42	9670-9699 : nhl - mature b-cell lymphomas
43	9700-9719 : nhl - mature t and nk-cell lymphomas
44	9720-9729 : nhl - precursor cell lymphoblastic lymphoma
45	9730-9739 : plasma cell tumors
46	9740-9749 : mast cell tumors
47	9750-9759: neoplasms of histiocytes and accessory lymphoid cells
48	9760-9769 : immunoproliferative diseases
49	9800-9805: leukemias, nos
50	9820-9839 : lymphoid leukemias (C42.1)
51	9840-9939 : myeloid leukemias (C42.1)
52	9940-9949 : other leukemias (C42.1)
53	9950-9969 : chronic myeloproliferative disorders (C42.1)
54	9970-9979 : other hematologic disorders
55	9980-9989 : myelodysplastic syndrome
98	other

HISTOLOGY RECODE—BRAIN GROUPINGS

NAACCR Item #: N/A

SEER*Stat Name: Histology recode - Brain groupings

Item Length: 2

01	Diffuse astrocytoma (protoplasma, fibrillary)
02	Anaplastic astrocytoma
03	Glioblastoma
04	Pilocytic astrocytoma
05	Unique astrocytoma variants
06	Oligodendroglioma
07	Anaplastic oligodendroglioma
08	Ependymoma/anaplastic ependymoma
09	Ependymoma variants
10	Mixed glioma
11	Astrocytoma, NOS
12	Glioma , NOS
13	Choroid plexus
14	Neuroepithelial
15	Benign & malignant neuronal/glial, neuronal & mixed
16	Pineal parenchymal
17	Embryonal/primitive/medulloblastoma
18	Nerve sheath, benign and malignant
19	Meningioma, benign and malignant
20	Other mesenchymal, benign and malignant
21	Hemangioma and hemagioblastoma
22	Lymphoma
23	Germ cell tumors, cysts, and heterotopias
24	Chordoma/chondrosarcoma
25	Pituitary
26	Craniopharyngioma
27	Neoplasm, unspecified, benign and malignant
97	Other Brain Histologies
98	Not Brain

CS SCHEMA

NAACCR Item #: N/A

SEER*Stat Name: CS Schema

Item Length: 2

Field Description: This data item groups primary site and ICD-O-3 histology into the

Collaborative Stage Schema.

01	LipUpper
02	LipLower
03	OthLip
04	BaseTongue
05	AntTongue
06	GumUpper
07	GumLower
08	OthGum
09	FOM
10	HardPalate
11	SoftPalate
12	OthMouth
13	BuccalMucosa
14	ParotidGland
15	SubmandibularGland
16	OthSalivary
17	Oropharynx
18	AntEpiglottis
19	Nasopharynx
20	Hypopharynx
21	OthPharynx
22	Esophagus
23	Stomach
24	SmallIntestine
25	Colon
26	Rectum
27	Anus
28	Liver
29	Gallbladder
30	ExtraHepaticDucts
31	Ampulla
32	OthBiliary
33	PancreasHead
34	PancreasBodyTail
35	OthPancreas
36	OthDigestive

NasalCavity 37 38 MiddleEar 39 MaxillarySinus 40 EthmoidSinus 41 OthSinus 42 GlotticLarynx 43 SupraLarynx 44 SubLarynx 45 OthLarynx 46 Trachea 47 Lung HeartMediastinum 48 Pleura 49 50 OthRespiratory 51 Bone 52 Skin 53 SkinEyelid 54 Melanoma MF 55 SoftTissue 56 57 Peritoneum 58 Breast 59 Vulva 60 Vagina 61 Cervix 62 Corpus 63 Ovary 64 FallopianTube 65 OthAdnexa 66 OthFemaleGen 67 Placenta 68 Penis 69 Prostate 70 Testis 71 OthMaleGen 72 Scrotum 73 Kidney 74 RenalPelvis 75 Bladder 76 Urethra 77 OthUrinary 78 Conjunctiva 79 MelanomaConjunctiva 80 OthEye

81

MelanomalrisCiliary

82	MelanomaChoroid
83	MelanomaOthEye
84	LacrimalGland
85	Orbit
86	Retinoblastoma
87	Brain
88	OthCNS
89	Thyroid
90	OthEndocrine
91	KS
92	Lymphoma
93	HemeRetic
94	OthIllDef

RACE RECODE (WHITE, BLACK, OTHER)

NAACCR Item #: N/A

SEER*Stat Name: Race recode (White, Black, Other)

Item Length: 1

Field Description: SEER collapses the information available on race for publication. See

population documentation on which race variable to use when merging with

different versions of population data.

For detailed information regarding major changes to this field, please see the

following website:

http://seer.cancer.gov/seerstat/variables/seer/yr1973 2007/race ethnicity

1	White
2	Black
	Other (American Indian/AK Native, Asian/Pacific Islander)
7	Other unspecified (1991+)
9	Unknown

RACE RECODE (W, B, AI, API)

NAACCR Item #: N/A

SEER*Stat Name: Race recode (W, B, AI, API)

Item Length: 1

Field Description: See population documentation on which race variable to use when merging

with different versions of population data.

For detailed information regarding major changes to this field, please see the

following website:

http://seer.cancer.gov/seerstat/variables/seer/yr1973_2007/race_ethnicity/.

Codes

1	White
2	Black
3	American Indian/Alaska Native Asian or Pacific Islander Other unspecified (1991+)
4	Asian or Pacific Islander
7	Other unspecified (1991+)
9	Unknown

ORIGIN RECODE NHIA (HISPANIC, NON-HISP)

NAACCR Item #: N/A

SEER*Stat Name: Origin recode NHIA (Hispanic, Non-Hisp)

Item Length: 1

Field Description: See population documentation on which race variable to use when merging

with different versions of population data.

0	Non-Spanish-Hispanic-Latino
1	Spanish-Hispanic-Latino

SEER HISTORIC STAGE A

NAACCR Item #: N/A

SEER*Stat Name: SEER historic stage A

Item Length: 1

Field Description: This field is produced by collapsing the detailed EOD information collected

by SEER. Over time several different EOD schemes have been used. Thus

caution should be used when doing trend analyses with this field.

For detailed information on staging differences over time, please review the

following website:

http://seer.cancer.gov/seerstat/variables/seer/yr1973_2007/lrd_stage/

0	In situ — A noninvasive neoplasm; a tumor which has not penetrated the basement membrane nor extended beyond the epithelial tissue. Some synonyms are intraepithelial (confined to epithelial tissue), noninvasive and noninfiltrating.
1	Localized — An invasive neoplasm confined entirely to the organ of origin. It may include intraluminal extension where specified. For example for colon, intraluminal extension limited to immediately contiguous segments of the large bowel is localized, if no lymph nodes are involved. Localized may exclude invasion of the serosa because of the poor survival of the patient once the serosa is invaded.
2	Regional — A neoplasm that has extended 1) beyond the limits of the organ of origin directly into surrounding organs or tissues; 2) into regional lymph nodes by way of the lymphatic system; or 3) by a combination of extension and regional lymph nodes.
4	Distant — A neoplasm that has spread to parts of the body remote from the primary tumor either by direct extension or by discontinuous metastasis (e.g., implantation or seeding) to distant organs, issues, or via the lymphatic system to distant lymph nodes.
8	Localized/Regional – Only used for Prostate cases.
9	Unstaged — Information is not sufficient to assign a stage.

AJCC STAGE 3rd EDITION (1988-2003)

NAACCR Item #: N/A

SEER*Stat Name: AJCC stage 3rd edition (1988-2003)

Item Length: 2

Field Description: Codes

	T C'	21	TITA
0	In Situ	31	IIIA
10	I	32	IIIB
11	IA	33	IIIC
12	IB	39	III, NOS
13	IC	40	IV
18	In Situ and I combined for bladder only	41	IVA
19	I, NOS	42	IVB
20	П	49	IV, NOS
21	IIA	88	Recode scheme not yet available
22	IIB	90	Unstaged
23	IIC	98	Not applicable
29	II, NOS	99	Error condition
30	III		

Coded only for 1988-2003 cases with the following ICD-O site codes:

Colon	C180:C189
Rectum	C199,C209
Lung and Bronchus	C340:C349
Breast	C500:C509
Cervix	C530:C539
Corpus uteri	C559, C530:C539
Ovary	C569
Vagina	C529
Vulva	C519
Oth fem gen	C510:C512, C589
Prostate	C619
Bladder	C670:C679

For staging criteria, please refer to

http://seer.cancer.gov/manuals/historic/comp_stage1.1.pdf

SEER MODIFIED AJCC STAGE 3rd ED (1988-2003)

NAACCR Item #: N/A

SEER*Stat Name: SEER modified AJCC stage 3rd (1988-2003)

Item Length: 2

Field Description: Codes

0	In Situ	31	IIIA
10	I	32	IIIB
11	IA	33	IIIC
12	IB	39	III, NOS
13	IC	40	IV
18	In Situ & I combined for bladder only	41	IVA
19	I, NOS	42	IVB
20	II	49	IV, NOS
21	IIA	88	Recode scheme not yet available
22	IIB	90	Unstaged
23	IIC	98	Not applicable
29	II, NOS	99	Error condition
30	III		

Coded only for 1988-2003 cases with the following ICD-O- codes:

Colon	C180:C189
Rectum	C199,C209
Lung and Bronchus	C340:C349
Breast	C500:C509
Cervix	C530:C539
Corpus uteri	C559,C530:C539
Ovary	C569
Vagina	C529
Vulva	C519
Oth fem gen	C510:C512,C589
Prostate	C619
Bladder	C670:C679

For staging criteria, refer to

http://seer.cancer.gov/manuals/historic/comp_stage1.1.pdf

SEER SUMMARY STAGE 1977

NAACCR Item #: 760

SEER*Stat Name: SEER summary stage 1977 (1995-2000)

Item Length: 1

Field Description: Coded only for 1995-2000 cases.

For more detail regarding site-specific staging exceptions, please review the

following website:

http://www.seer.cancer.gov/seerstat/variables/seer/yr1973 2007/lrd stage/.

Codes

0	In situ
1	Localized only
2	Regional by direct extension only
3	Regional lymph nodes involved only
4	Regional by both direct extension and lymph
5	Regional, NOS
7	Distant site(s)/node(s) involved
9	Unknown/unstaged/unspecified/DCO

SEER SUMMARY STAGE 2000

NAACCR Item #: 759

SEER*Stat Name: SEER summary stage 2000 (2001-2003)

Item Length: 1

Field Description: Coded only for 2001-2003 cases.

0	In situ
1	Localized only
2	Regional by direct extension only
3	Regional lymph nodes involved only
4	Regional by both direct extension and lymph
5	Regional, NOS
7	Distant site(s)/node(s) involved
9	Unknown/unstaged/unspecified/DCO

NUMBER OF PRIMARIES

NAACCR Item#: N/A

SEER*Stat Name: Number of primaries

Item Length: 2

Field Description: Number reflects the actual number of primaries based on the total number of

records/tumors in SEER, not necessarily this database file. This value is the

same across all records for a person.

Codes

01-27 Actual number of primaries

FIRST MALIGNANT PRIMARY INDICATOR

NAACCR Item #: N/A

SEER*Stat Name: First malignant primary indicator

Item Length: 1

Field Description: Based on all the tumors in SEER. Tumors not reported to SEER are assumed

malignant.

Codes

0	no
1	yes

STATE-COUNTY RECODE

NAACCR Item #: N/A

SEER*Stat Name: State-county

Item Length: 5

Field Description: This item is a state-county combination where the first two characters

represent the state FIPS code. The last three digits represent the FIPS county

code.

SURVIVAL TIME RECODE

NAACCR Item #: N/A

SEER*Stat Name: Survival time recode (month)

Survival time recode (year)

Item Length: 4

Field Description: The Survival Time Recode is calculated using the date of diagnosis and one

of the following: date of death, date last known to be alive, or follow-up cutoff date used for this file (see title page for date for this file). Thus a person diagnosed in May 1976 and who died in May 1980 has a Survival

Time Recode of 04 years and 00 months.

Codes

YYMM where:

YY = number of completed years MM = number of completed months

9999 = unknown--Survival Time Recode cannot be calculated for this case

EXAMPLE:

Assume December 1985 is used as a follow-up cutoff date:

- 1. If a person was known to be alive in April of 1986, December 1985 is used to compute Survival Time Recode.
- 2. A person known to have died in May 1987 is considered alive and Survival Time Recode computed using December 1985 as date of last contact.
- 3. If the last information on a person is that s/he was alive in April 1980, then April 1980 is used.

CAUSE OF DEATH TO SEER SITE RECODE

NAACCR Item #: N/A

SEER*Stat Name: COD to site recode

Item Length: 5

Field Description: This recode was introduced to account for several newly valid ICD-10 codes

and includes both cancer and non-cancer causes of death.

See the following website for details:

http://seer.cancer.gov/codrecode/1969+ d09172004/index.html

COD TO SITE REC KM

NAACCR Item #: N/A

SEER*Stat Name: COD to site rec KM

Item Length: 5

Field Description: For details on COD to SEER site recode with Kaposi sarcoma and

mesothelioma, see the link below:

http://seer.cancer.gov/codrecode/1969+ d09172004/index.html

VITAL STATUS RECODE

NAACCR Item #: N/A

SEER*Stat Name: Vital status recode (study cutoff used)

Item Length: 1

Field Description: Any patient that dies after the follow-up cut-off date is recoded to alive as of

the cut-off date.

Codes

1	Alive
4	Dead

IHS LINK

NAACCR Item #: 192

SEER*Stat Name: IHS Link

Item Length: 1

Field Description: This variable captures the results of the linkage of the registry database with

the Indian Health Service patient registration database for November 2008.

0	Record sent for linkage, no IHS match
1	Record sent for linkage, IHS match
Blank	Record not sent for linkage

SUMMARY STAGE 2000 (1998+)

NAACCR Item #: N/A

SEER*Stat Name: Summary Stage 2000 (1998+)

Item Length: 1

Field Description: Taken from Collaborative Stage (CS) for 2004+ and extent of disease (EOD)

prior to that. Used in most SEER publications. For more information, see http://seer.cancer.gov/seerstat/variables/seer/yr1973 2007/lrd stage.

AYA SITE RECODE

NAACCR Item #: N/A

SEER*Stat Name: AYA site recode

Item Length: 2

Field Description: Adapted classification schema for tumors of adolescents and young adults.

For more information, see http://seer.cancer.gov/ayarecode.

LYMPHOMA SUBTYPE RECODE

NAACCR Item #: N/A

SEER*Stat Name: Lymphoma subtype recode

Item Length: 2

Field Description: A detailed categorization of lymphoma subtypes. For more information, see

http://seer.cancer.gov/lymphomarecode/.

SEER CAUSE-SPECIFIC DEATH CLASSIFICATION

NAACCR Item #: N/A

SEER*Stat Name: SEER cause-specific death classification

Item Length: 1

Field Description: The variable seeks to determine whether a patient died from their cancer

using site, sequence number and cause of death. Patients who died of something determined to be unrelated are treated as if they were alive. It was designed specifically to be used as the determinant of cause-specific survival

analysis.

For more information, see http://seer.cancer.gov/causespecific.